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The goal of this research was to develop and understand an anesthetized, multiple-seizure 
rat model for local epilepsy.  Local seizures are not as well understood as global seizures due to 
their specificity and unpredictability.  Furthermore, patients are diagnosed with epilepsy after 
experiencing two or more unprovoked seizures.  In this model, two separate seizure episodes were 
induced by locally administering the epileptic agent 3-mercaptopropionic acid through a 
microdialysis probe to the CA1 region of the hippocampus.  Upon development of the model, 
attenuation in glutamate release was observed in the second seizure stimulation.  To investigate 
neurochemical and biochemical pathways which may be responsible for the glutamate diminution, 
the perfusion fluid was spiked with either glucose, lactate, or dihydrokainic acid.  Additionally, as 
it is well known that high levels of extracellular glutamate can result in excitotoxicity, neuronal 
staining was performed to determine the neuronal viability after the induction of the first seizure.  
It was determined that the attenuation in glutamate release in the second seizure episode was 
primarily due to a combination of mitochondrial starvation and cell damage.    
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The local seizure model was then used to correlate local seizure induction to oxidative 
damage.  Glutathione (GSH) and malondialdehyde (MDA) were selected as biomarkers of 
oxidative stress.  Intracellular levels GSH were up regulated and down regulated in hopes of 
modifying the amount of seizure induced oxidative damage.  There was no statistically significant 
change in MDA formation with changing GSH levels; however, GSH did appear to serve as a 
release modifier of the redox cycle.  Extracellular GSH increased significantly during the seizure 
induction and returned to basal after the seizure ended.  This increase in extracellular GSH 
concentration can be accounted for by astrocytes and glial cells releasing GSH to counteract 
reactive oxygen species produced during the seizure.  Additional experiments need to be done in 
order to make further conclusions; however, it is evident that there is a correlation between seizures 
and oxidative stress.       
Finally, Appendix I describes a small in vitro pharmacokinetic project using microdialysis 
sampling to measure plasma protein binding values of commercially available drugs with the 
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Chapter 1  
Introduction 
1.1  Oxidative Stress Overview 
Oxidative stress is a result of the imbalance between the production of free radicals and the 
body’s ability to counteract them through antioxidants.  Oxidative stress can lead to a wide range 
of negative outcomes including cancer, neurodegeneration, DNA damage, and cell death1.  There 
are many factors that can result in oxidative stress including exposure to chemicals, consumption 
of processed food, and neurological disorders2, 3.  The brain is rich in fatty acids that are highly 
susceptible to oxidative damage, peroxidation and radical production4.  One of the most common 
neurological disorders, epilepsy, is believed to cause oxidative stress in the brain3, 5, 6.  Epilepsy is 
a result of an imbalance in the neurotransmitters in the brain that causes an activation of G-protein 
coupled receptors that change calcium ion concentrations at the neuronal membrane7.  This change 
in membrane potential results in the production of reactive oxygen species (ROS) such as 
peroxides, superoxide, and the hydroxide radical through a variety of mechanisms.  These ROS 
can lead to lipid peroxidation, neuronal damage, changes in neuronal plasticity, and cell death that 
can, in turn, result in subsequent seizures (Figure 1.1)8.  Studies have shown that epileptic seizures 
tend to induce long-term hyperexcitability in neurons, making them more prone to future seizures9.  
This cycle of excitotoxicity continues until the damage is irreparable.  Therefore, it is imperative 
to gain a better understanding of the biochemical pathways involved in the production of oxidative 
stress during seizures, in hopes that this cycle can be broken and therapeutic treatments can be 























1.2 Epilepsy Overview 
Epilepsy affects approximately one percent of the world population10.  There is currently no 
known cure for epilepsy and only 70% of epileptic cases can be regulated with medication.  This 
leaves nearly 30% of epileptic patients with a pharmacoresistant form of epilepsy that cannot be 
treated with medication10.  There are several alternative treatments available for pharmacoresistant 
seizures including, special diets11, surgery12, and deep brain stimulation13, 14.  Success has been 
achieved for all treatments; however, there are still cases that remain untreatable.   
An epileptic event, or seizure, is caused by an imbalance of the neuronal firing in the brain. 
When the inhibitory responders are not able to offset the excitatory responders, a seizure is 
observed7, 15.  There are two main categories of seizures, local and global (tonic-clonic).  Seizures 
that occur locally affect only one region of the brain, whereas global seizures affect multiple brain 
regions.  Nearly 70% of epileptic patients experience local seizures6.  Local seizures, due to their 
specificity and unpredictability, are not as well understood as global seizures16, 17.  Furthermore, 
symptoms of local seizures are not as severe as global seizures, thus making them harder to 
diagnose.  There are many models available for global seizures, including knockout mice and the 
systemic dosing of the animal with convulsants16, 18, 19.  However, there are only a few models that 
locally dose convulsants to a specific brain region to generate multiple local seizures.  In some 
studies of epilepsy, single seizures were induced in the brain region of interest both chemically 
and electrically20, 21.  However, patients are diagnosed with epilepsy after having experienced two 
or more unprovoked seizures6, 9.  To date, there are no reported models that induce multiple local 
seizures within one experiment, meaning there is no model that represents local epilepsy.  
Generating multiple seizures in a localized brain region within the same experiment will provide 
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neurochemical insights into local epilepsy.  Direct comparisons of analyte concentrations can be 
made between the first and second seizure as well as intraseizure neurochemical response.        
 
1.3 Animal Seizure Models 
There are two main types of animal models used to simulate epilepsy, stimulated and kindling 
models7, 19.  With stimulated models, a convulsion is induced either electrically with electrode 
firing or chemically by dosing the animal with a convulsant, resulting in an instantaneous seizure.  
In kindling models, a subconvulsant dose of an epileptic agent, or a subthreshold electrical 
stimulus is administered over time until the animal develops a sensitivity to the stimulation that 
leads to spontaneous seizures.  This approach induces unpredictable seizures22.  While the kindling 
model more accurately represents epileptic seizures with the inherent unpredictability, these 
seizures are difficult to replicate in a laboratory setting.  For this reason, stimulated seizures were 
used in this research.  Kindling models are discussed further in Chapter 5.  
 
1.3.1 Electrically Induced Seizures 
Electrodes can be implanted directly into the brain region of interest. An electric current is 
deployed that disrupts the neurons and causes misfiring, resulting in a seizure14, 23, 24.  A major 
advantage of electrically induced seizures is that they do not rely on a chemical to generate a 























as can be seen in Figure 1.2, the electrically stimulated model has a loss of spatial resolution 
associated with this type of stimulation.   The brain of a rat is small and there is not much room to 
implant both electrodes for stimulation and microsampling probes for sample collection.  The 
collection probe may not be in the same brain region as the stimulating electrodes, reducing spatial 
resolution and possibly resulting in measurement of false responses.    
 
1.3.2 Chemically Induced Seizures 
Chemically simulated models negate the need for electrode implantation.  A convulsant 
dose of an epileptic agent is directly given to the animal, causing an imbalance in signaling of two 
of the most abundant excitatory and inhibitory neurotransmitters, glutamate and γ-aminobutyric 
acid (GABA), thereby resulting in a seizure25, 26.  There are three main types of convulsants 
available including those that affect glutamate receptors, GABAergic receptors, and the synthesis 
and metabolism of GABA.   
Agonists of glutamate receptors work by directly activating glutamate receptors that form 
the network of the major excitatory neurotransmitter in the brain, thus leading to abnormal 
electrical discharges27, 28.  Drugs that work on GABAergic receptors (GABAA and GABAB) act by 
blocking the GABA receptors, thus removing the activity of the main inhibitory neurotransmitter 
in the brain29, 30. The final category of convulsants alters the synthesis and metabolism of GABA.  
Glutamic acid decarboxylase (GAD) is the enzyme that converts glutamic acid to GABA via a 
decarboxylation reaction25, 26, 31.  By using a chemically induced seizure model, both seizure 
duration and strength can be controlled by varying administration time and compound 
concentration.  Additionally, experiments can be replicated with ease because the experimenter 
determines when the seizure occurs, making it ideal for the laboratory setting.        
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1.3.2.1 3-Mercaptopropionic Acid  
3-Mercaptopropionic acid (3-MPA) is a well-established chemical convulsant that functions 
as a competitive inhibitor of GAD, creating an imbalance in glutamate and GABA 
concentrations32, 33 (Figure 1.3). This results in an increase in extracellular glutamic acid 
concentrations and a decrease in GABA concentrations, simulating a seizure34.  The exact 
mechanism of action has been previously described elsewhere20, 32, 35, 36, but briefly, the structural 
similarity of 3-MPA and GABA makes 3-MPA an excellent competitive inhibitor of GAD.  GAD 
metabolizes the 3-MPA in the same way that it would glutamic acid.  It is a reversible inhibitor 
and, when there is no longer 3-MPA available to block the active site of the enzyme, then GAD 
continues to function normally, converting glutamic acid into GABA.  Its reversible properties 
make it a good choice for a convulsant.   
 
1.4 Methods 
1.4.1 Microdialysis Sampling 
The main sampling and delivery technique used in this research was microdialysis 
sampling.  Microdialysis sampling involves a relatively simple system consisting of a probe, 
connecting tubing, and a perfusion pump37.  The active area of the probe consists of a 
semipermeable membrane that provides chemical communication between the probe lumen and 
the surrounding tissue space.  To perform microdialysis sampling, the probe is slowly perfused 
with a solution termed the perfusate that closely matches the composition of the extracellular fluid 





















any concentration difference across the membrane.  Molecules can diffuse across the membrane 
in either direction depending on the direction of the concentration gradient allowing for both 
recovery/sampling of compounds from the target tissue as well as delivery of compounds to the 
tissue37, 40.  Typical microdialysis membranes have molecular weight cutoffs between 10-100 kDa 
that prevent macromolecules, such as proteins, from crossing into the dialysate sample. Because 
large molecules are excluded from entering the probe, microdialysis samples are protein-free and 
typically require no additional sample clean up prior to analysis. 
 
1.4.2  Type of Probes 
There are several microdialysis probe designs available that allow for sampling in a variety 
of tissues and systems, which can be seen in Figure 1.4.  The tissues and analytes being studied 
determine the type of probe to be used.  The most common microdialysis probe for brain sampling 
is the concentric cannula style (Figure 1.5)41, 42.  In the concentric style, the inlet and outlet tubing 
are on the same side of the probe and the membrane is on the other end.  This style is favored in 
the brain because it allows for only one entry site, reducing tissue damage.  In this set-up, a guide 
cannula containing a dummy probe is implanted into the region of interest and fixed to the skull 
using dental cement, guaranteeing that the probe remains in the correct region for the duration of 
the experiment.  The dummy probe is then replaced with a stainless steel microdialysis probe for 
sampling.   
Another probe type used for microdialysis studies is the flexible probe.  Similar to the 
concentric cannula, the flexible cannula still allows for a single implantation site because the inlet 
and outlet are on the same side of the probe, however, it is not as rigid.  Rather than the unyielding 










Figure 1.4: Four of the most common probe types.  A) Shunt probe B) Linear probe C) Flexible 














Figure 1.5: Concentric cannula probe system. CMA 12 Elite Microdialysis Probe 












that is able to be implanted into vessels and other peripheral tissues43.  In some experiments, a 
combination of a brain probe and flexible probe are used for blood brain barrier studies.  A stainless 
steel concentric cannula probe is implanted into the brain to measure analyte concentration in the 
brain, while a flexible probe is implanted into a blood vessel to measure analyte concentrations in 
the blood.  Simultaneous sampling from both the brain and blood can be done and direct 
concentration comparisons can be made44.   
The brain probe and flexible probe were the two main probes used in this research.  Another 
common type of probe is the linear probe.  Similar to the flexible probe, the linear probe is 
preferred for use in peripheral tissues due to its flexible property.  It allows the animal to move 
freely while causing minimal damage to the tissue.  In contrast to the concentric cannula and 
flexible probe designs, the linear probe has inlet and outlet tubing on opposite sides of the 
membrane43, 45.  This allows for longer membrane lengths than other probe styles, which results in 
better sample recovery due to the increased surface area of the probe in the tissue.  The last major 
type of probe style is the shunt probe.  While not as common, the shunt probe is a good system for 
damage-free collection of fluids.  A shunt is inserted into the desired location and then a linear 
probe is placed inside of the shunt.  This microdialysis probe was specifically designed for 
sampling the bile while maintaining normal bile flow and volume39.   
 
1.4.3 Theory 
Microdialysis is based on the same principles and concepts of large scale dialysis (Figure 
1.6).  Analytes passively diffuse across the semipermeable membrane down their concentration 
gradient according to Fick’s Law37, 46.  Unlike large scale dialysis, equilibrium is not achieved in 








Figure 1.6: Schematic demonstrating microdialysis sampling mechanism 
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quickly established.  There are several factors that affect how the steady-state is established 
including the perfusion fluid, perfusion rate, membrane type, membrane length, molecular weight 
cut-off, and composition of the tissue of implantation40, 47.   
Hydrophilicity of analytes must be taken into consideration when choosing a perfusion 
fluid and membrane type.  Highly lipophilic compounds may have lower recovery if the perfusion 
fluid or membrane is highly hydrophilic.  Higher flow rates of the perfusate allow for larger sample 
volumes, increasing the absolute recovery, but also results in dilution.  The faster flow reduces the 
amount of time that analytes can diffuse across the probe and be collected, reducing overall relative 
recovery.  An example plot of relative recovery versus flow rate is shown in Figure 1.7.  Longer 
membrane lengths provide more room for analytes to cross but reduce spatial resolution for in vivo 
studies.  Therefore, the shortest membrane length that provides adequate recovery is ideal for 
maintaining good spatial resolution.  Choosing a membrane with a molecular weight cut-off that 
limits the amount of macromolecules in your sample reduces the need for extensive sample clean-
up.  Finally, composition of sample/tissue also affect recovery due to the complexity of the matrix 
and the possibility of analyte metabolism.  All of these factors can lead to recoveries less than 
100%, meaning the concentration of analyte in the dialysate is not the same as the true 
concentration of analyte in the tissue, but rather a relative amount.   
 
1.4.3.1 Microdialysis Calibration Methods 
In order to calibrate the microdialysis probe, recovery and delivery experiments performed 
in vitro can be used to determine the extraction efficiency of the probe; this efficiency can then be 










































1.  In a relative recovery experiment, a bath solution containing sample matrix is maintained at 
37°C and stirred constantly.  The bath solution is spiked with a known concentration of analyte.  
The probe is placed in the solution and blank sample matrix is perfused through the probe for a set 
length of time.  As the perfusion occurs, analyte in the bath solution is allowed to passively diffuse 
across the membrane and be collected in the dialysate.  The concentration of analyte in the 







In vitro delivery experiments can also be used as a form of probe calibration.  In a similar 
set-up to recovery experiments, the probe is placed in a bath solution heated to 37°C and stirred 
constantly containing unspiked sample matrix.  The perfusion fluid is spiked with a known 
concentration of analyte.  Perfusion is allowed to occur for a set length of time, dialysate is 
collected, and analyte concentration is analytically determined.  The delivery of the compound to 
























 While these techniques work well for in vitro experiments where analyte concentration can be 
controlled, probe calibration is more difficult in vivo because the concentration of analyte in the 
sample is unknown and there are additional factors such as tortuosity and metabolism that can 
affect analyte recovery.  Because of this, several methods for determining probe recovery in vivo 
have been developed.   
Using the ”no-net-flux” method described by Lonnroth et al., the expected in vivo analyte 
concentration is bracketed using varying concentrations of analyte in the perfusate38.  Once the 
concentration of the analyte in the perfusate is greater than the in vivo concentration, the analyte 
will begin to diffuse into the tissue.  Conversely, when the concentration of analyte in the perfusate 
is lower than the concentration in the tissue, the analyte will diffuse from the tissue into the 
dialysate.  An example plot of concentration in perfusate versus concentration in dialysate is shown 
in Figure 1.8.  The plot is then used to determine the concentration of analyte in the tissue, which 
is the point at which there is no-net-flux, represented in red in Figure 1.8.  Unfortunately, this 
method is very time consuming and is not a practical method for monitoring analytes whose 
concentration can change rapidly in vivo.    
Another, simpler method for determining probe recovery in vivo is using retrodialysis49.  
Retrodialysis is also known as relative delivery.  In the same manner as determining delivery in 
vitro, retrodialysis employs spiking the perfusate with a known concentration of an internal 
standard.  The recovery of the analyte is then estimated based on the concept that the delivery 
across the membrane is the same as recovery across the membrane.  While this method is much 
simpler than no-net-flux, it does not take biological conditions (ischemia, reperfusion, metabolism, 









































difference between no-net-flux and retrodialysis for a wide range of analytes50, 51, and for this 
reason it was employed for all experiments in this research.     
 
1.4.4 Other Sampling Techniques 
While microdialysis sampling is currently the most common continuous in vivo 
microsampling technique, other microsampling techniques such as push-pull sampling, 
ultrafiltration, microextraction, and rapid equilibrium dialysis can also be used to achieve similar 
results.  Each method has its own advantages and disadvantages.  Some of these microsampling 
methods can be used to address certain limitations of microdialysis.  While each of the 
aforementioned methods have been used for many years, recent developments have resulted in 
their increased utility for in vivo microsampling46. 
Ultrafiltration is an in vivo microsampling technique that is similar to microdialysis in that 
sampling occurs across a semipermeable membrane.  For ultrafiltration sampling, a vacuum is 
applied to the probe and sampling occurs via bulk transport of ECF into the probe instead of via 
diffusion as with microdialysis sampling.  Since bulk ECF is collected, the analyte concentration 
in the sample is the same as that in the tissue and calibration is not required.  Like microdialysis, 
the ultrafiltration membrane excludes macromolecules making sample analysis easier52.  Since 
ECF is removed from the sampling site, only tissues with high ECF volumes can be sampled 
without significant perturbation.  The most common sampling sites for ultrafiltration have been 
the subcutaneous tissue or fluids such as blood.  Denser tissues such as brain tissue are unsuitable 
for ultrafiltration sampling.  Because of these limitations, ultrafiltration is not a very common 
method for in vivo sampling but is often used for environmental sampling53.   
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The push-pull perfusion method is similar to microdialysis but does not use a membrane. 
Rather, two syringe pumps are employed with one delivering solution to the sampling site through 
one cannula and the other used to pull ECF sample from the second cannula54. The sample is thus 
collected via the pulling syringe and the ECF removed is replaced by the pushing syringe.  Since 
bulk ECF is collected through the pull syringe, if the flow is not too high, the concentrations of the 
analytes in the sample are the same as in the tissue.  Therefore, calibration can typically be avoided 
and because there is no membrane, all size molecules are collected.  Thus, push-pull perfusion is 
directly amenable to sampling peptides and proteins.  The major problems associated with the 
initial push-pull approaches resulted from the force of the push solution causing tissue damage and 
the pulling cannula being prone to clogging.  However, new, low-perfusion push-pull techniques 
have been developed which allow for a decrease in sample volume while still maintaining good 
analyte recovery and reducing tissue damage46. 
Another alternative to microdialysis sampling is microextraction.  Microextraction is a 
sampling technique that requires the insertion of a small, semipermeable probe into the desired 
system.  Typically, the membrane is sheathed by a needle that is inserted into the tissue of interest.  
The membrane is on a solid support that is then ejected out of the needle into the tissue where 
diffusion of analytes into the probe is allowed to occur.  After the allotted amount of time, the 
membrane is inserted back into the needle and then the needle is removed from the system55.  
Microextraction eliminates the need for excess solvent and also has a short sample collection time 
compared to push-pull perfusion.  Possibly the biggest benefit to microextraction is the direct 
filtration and purification of the sample via solid-phase extraction.  Generally, microextraction 
probes are connected to a filtration syringe that contains a solid phase purification system55.  This 
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removes the need for sample preparation and allows for direct injection into an analytical 
instrument.   
Microextraction can be performed on a small scale, which allows for the collection of samples 
in delicate in vivo systems such as blood capillaries.  While microextraction is minimally invasive, 
not replenishing fluid can create problems in sample collection.  The lack of perfusion through the 
probe can also result in clogged probes.  Tissue dehydration and damage can result because fluid 
is being collected from the tissue and not being replaced.  The microextraction method of 
microsampling allows for the collection of analytes of high molecular weights, which makes this 
method attractive for peptide and protein studies.  Recent probe development has increased the 
number of semipermeable probes that are inserted into the tissue at one time56.  This has increased 
sample through-put, allowing for more samples to be obtained at one time. 
 
1.5 Liquid Chromatography Overview 
Because microdialysis sampling produces clean, protein free sample, additional sample 
clean-up is usually not required, however, implementing a separation method is advantageous.  
This allows for the easy identification of multiple analytes within the complex in vivo samples.  
Liquid chromatography (LC) is a widely used separation technique that has been around since the 
1960s57.  LC separations are based on the interaction of the analyte with the stationary phase and 
the mobile phase.  There are several different types of stationary phases that can be employed, 
which are discussed later.  Compounds will partition between the stationary phase and the mobile 
phase based on their affinity for the phase.  Retention time is based on the amount of time the 






























The mobile phase flows through the pump tubing and an injector port and then flows through the 
column for separation.  The flow continues to allow the analytes to reach the detector that produces 
a signal that gets translated to the computer as output.  The mobile phase is typically filtered and 
degassed to remove any contaminates, particulates, and oxygen.  There are two main types of 
mobile phase separations, isocratic and gradient57.  In an isocratic separation, a single pump is used 
with a single bottle of mobile phase.  This is the simplest LC operation and works well for 
compounds with similar capacity factors and structures.  When analytes have a wide range of 
capacity factors, structures, or chemical properties it becomes necessary to implement a gradient.  
In this LC operation mode, two pumps are used with two bottles of mobile phase, one containing 
a high aqueous composition and one containing a high organic composition.  By using a gradient, 
the partitioning of compounds is altered quickly, causing highly retained compounds to elute 
earlier.  This allows for the separation of a wide variety of compounds within one analysis run. 
 
1.5.1 Theory 
How long the analyte is retained on the column is mathematically described by the capacity 
factor k’, Equation 3, where tr is the retention time of the analyte and tm is the retention time of 
non-retained compounds.  The capacity factor of a compound is determined by the amount of time 










The longer that compounds are retained on the column, the more time available for separation to 
occur.  Because there is a set flow rate and run time, all compounds will spend the same amount 
of time in the mobile phase, meaning the separation of multiple compounds will depend on the 
amount of time spent in the stationary phase58.  Selectivity, α, is mathematically determined in 
Equation 4.  The capacity factors for two analytes are used to determine the stationary phase’s 









Additional chromatographic factors that affect separation include column efficiency (Equation 5), 
resolution (Equation 6), and theoretical plates (N) and plate height (H) (Equation 7).  Column 
efficiency affects the width of the peaks.   
 









A larger N value results in more narrow peaks.  More narrow peaks means more space for more 
compounds to be separated.  Resolution is the ability to distinguish two analytes based on their 
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retention time, represented at Rs in Equation 6.  Ideally, compounds should be baseline resolved, 














Finally, theoretical plates and plate height represent a hypothetical zone of equilibrium between 
the mobile phase and the stationary phase58.  L is the length of the column, represented in Equation 
7.  Longer columns allow for greater separation capacity but can also result in higher diffusion and 









The larger the number of theoretical plates (N), the more efficient the column.  Similarly, the 
shorter the plate height (H), the more efficient the column, which can be observed in the Van 
Deemter equation (Equation 8).  This equation demonstrates how band broadening determines 
plate height59.  In this equation, the multiple paths term (A) represents Eddy Diffusion.  Because 
the column is packed with material, there are going to be multiple path options that the analyte can 
take to make its way to the outlet.  This will result in band broadening because a portion of the 
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analyte will take a faster path and a portion of the analyte will take a slower path.  B represents 
longitudinal diffusion that occurs in the direction of the flow.  The longitudinal diffusion considers 
that the compound will not only be moving horizontally with the flow, but also vertically within 
the column.  Finally, C is the mass transfer term which represents the movement of the mobile 
phase through the stationary phase.  The flow rate is represented by µ.  Packing material, column 
parameters, flow rate, and mobile phase composition can all be adjusted and optimized in order to 
reduce these effects, thereby decreasing plate height and increasing separation efficiency.    
 








1.5.2 Stationary Phase 
Analyte properties are used to help determine which type of column and mobile phase are 
required for separation.  Normal phase, reverse phase, ion exchange, and size exclusion 
chromatography are the four most commonly used stationary phases.  Reverse phase is by far the 
most common type of stationary phase and consists of a silica base with carbon chains, typically 
C-18 or C-8, making it a nonpolar stationary phase.  Reverse phase C-18 columns were used in 
this thesis.  Mobile phases with high aqueous content are used with this type of column so that 
hydrophilic compounds will elute first and hydrophobic compounds will be retained longer.  
Gradients can be used to increase organic concentration in the mobile phase and force the 
27 
 
hydrophobic compounds off the column.  Modifiers can be added to both the mobile phase and 
stationary phase to improve retention and elution60.            
Normal phase chromatography involves a stationary phase that is more polar than the 
mobile phase, such as silica.  Ion exchange chromatography uses either a cationic or anionic 
stationary phase to separate compounds based on their charge.  Finally, size exclusion 
chromatography uses a stationary phase with pores that analytes are able to diffuse in and out of 
based on their size.  All modes of separation have their benefits and it is critical to pick a stationary 
phase based on the analytes to be studied.   
 
1.5.3 Fluorescence Detection of Amino Acid Neurotransmitters 
There are many types of detection methods available to analytically determine analytes, 
each with its own benefits and drawbacks.  Fluorescence detection was chosen for this study 
because it is a highly sensitive method that works for the analysis of many amino acids.  According 
to Jablonski, fluorescence occurs when a molecule absorbs a photon at one wavelength and then 
emits that photon at a different wavelength due to the release of energy from the vibrational and 
rotational states61.  Because energy is emitted from the compound, fluorescence is a direct 
measurement, making it more sensitive than UV-Vis which is a subtractive technique.  Compounds 
that are highly conjugated are easily detected by fluorescence; because of their pi bonds, they have 
more orbitals into which the electrons may be excited and relaxed62.  For compounds that are not 
highly conjugated, such as the amino acids measured in this thesis, a derivatization reagent such 
as naphthalene-2,3-dicarboxaldehyde or o-phthalaldehyde-2-mercaptoethanol may be used to 




1.5.4 Electrochemical Detection of Catecholamine Neurotransmitters  
Another mode of detection that provides the limits of detection required for neurochemical 
studies is electrochemical detection.  Two of the most common electrochemical detection (EC) 
methods are voltammetry and amperometry.  Both types of EC typically consist of a working 
electrode, a reference electrode, an auxiliary electrode, and a potentiostat and can be used for the 
analysis of electrochemically active compounds.  A potential is applied by the potentiostat to the 
working electrode against a reference electrode.  This ensures that the working electrode is 
experiencing consistent applied voltage.  Additionally, because the faradaic current flows between 
the auxiliary electrode and the working electrode, a drop in potential, known as iR-drop, is avoided, 
further ensuring that the voltage being applied to the working electrode is correct 63, 64.  Working 
electrodes can be made of a variety of materials such as glassy carbon, carbon paste, gold, 
gold/mercury amalgam, and platinum.  Reference electrodes are normally Ag/AgCl and the 
auxiliary electrode is typically made of electrochemically inert material like gold or platinum.  
In cyclic voltammetry, the electrode potential is scanned over a range in a cyclic fashion.  
The applied voltage versus measured current is then plotted.  In amperometry, the electrode 
potential is held constant through the duration of the run and is typically at a positive potential to 
encourage oxidation of analytes or a negative potential to encourage reduction of analytes.  As the 
molecules interact with the surface of the electrode, current flows to or from the electrode based 
on the oxidation or reduction of the compound.  This change in current produces a measureable 
signal65.  The electrode serves as either an oxidizing agent or a reducing agent depending on the 
potential, making it a valuable detection method for all electrochemically active compounds, 




1.5.5 Mass Spectrometry – Commercially Available Drug Detection 
The last detection method that was used in this research was mass spectrometry.  Mass 
spectrometry (MS) provides a highly sensitive detection method based upon the mass-to-charge 
ratio and abundance of the analyte.  Mass spectrometric analysis requires three main components: 
an ionizer, a mass analyzer, and a detector.  The ionizer produces gas phase charged ions of the 
analyte.  There are a variety of ionizers that can be used depending on the analyte and sample 
matrix.  A few examples include fast atom bombardment, atmospheric-pressure chemical 
ionization, matrix-assisted laser desorption/ionization, and electrospray ionization66.  In this 
research, electrospray ionization was used, which utilizes a high voltage spray of electrons to 
bombard the analyte, thereby creating an aerosol of ions which gets sent to the mass analyzer.  
Mass analyzers separate ions based on their mass-to-charge ratio.  Some of the most common mass 
analyzers include time-of-flight, ion trap, and quadrupole.  For the purpose of this research a triple 
quadrupole mass analyzer provided sufficient sensitivity for the study.  A quadrupole mass 
analyzer uses oscillating electrical fields that either stabilize or destabilize the path of the ions 
toward the detector67.  Ions will approach the detector depending on their mass-to-charge ratio and 
the potential of the 4 oscillating poles.  In a triple quadrupole mass analyzer, the analyte must pass 
through three quadrupoles to reach the detector.   The first functions as a mass analyzer to separate 
out the molecule with the mass-to-charge ratio of interest.  This is known as the parent ion.  The 
second quadrupole functions as a collision chamber, fragmenting the molecule into product or 
“daughter” ions.  The final quadrupole also works as a mass analyzer and can be used to transmit 
the product ions of interest toward the detector.  By fragmenting the parent ion and detecting the 
daughter ions, selectivity is greatly increased68.  Finally, ions that reach the detector are then 
converted from charge/current to signal, typically using an electron multiplier.       
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1.6 Overview of the Research 
The goal of the research was to develop and optimize a rat epilepsy model exhibiting 
multiple local seizures.  Because patients are diagnosed with epilepsy after having two or more 
unprovoked seizures, two seizure episodes were induced within the same experiment.  Only local 
seizures were explored, as they are not as well understood as global seizures.  Chapter two 
discusses the development of an anesthetized, multiple-seizure rat model for epilepsy.  In this 
model, two local seizures stimulations were induced by locally dosing 3-mercatopropionic acid 
directly into the hippocampus of an anesthetized rat using microdialysis.  Samples were collected 
and analyzed for both catecholamine and amino acid neurotransmitters.  Various time dosing 
regimens were explored to determine if time between seizures affected the biochemical responses 
to the epileptic agent.  Upon development of the model, unexpected attenuation in glutamate 
release was observed in the second seizure stimulation.  Because the ultimate goal of the research 
was to thoroughly investigate multiple seizures at a neurochemical level, a series of experiments 
were conducted to determine the cause of such attenuated glutamate release.  Chapter three 
discusses these studies.   
In Chapter 3, the same experimental procedures as in chapter two were followed; however, 
several neurochemical pathways were investigated to determine the cause of the glutamate release 
attenuation.  Metabolic, energy, and transport pathways were investigated by spiking the perfusion 
fluid with either glucose, lactate, or dihydrokainic acid.  Neuronal staining was also performed to 
determine the amount of viable neurons after the induction of the first seizure.  Once the model 
was better understood, correlations between local epilepsy and oxidative stress could be made.   
Chapter four discuss experiments that were performed to investigate the upregulation and 
downregulation of biomarkers of oxidative stress associated with epilepsy.  Thiol levels were 
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depleted by buthionine sulfoxime or enhanced by ɣ-glutamylcysteine ethyl ester.  Upregulation 
and downregulation of oxidative stress biomarkers during epileptic seizures allowed for 
conclusions to be made about the secondary oxidative effects of epilepsy.  Chapter five is a 
summary of the research conducted, conclusions, and future directions of the research.   
Finally, appendix one discusses a smaller in vitro pharmacokinetic project that was 
conducted using microdialysis.  In this study, 12 different commercially available drugs were 
individually spiked in human plasma to determine plasma protein binding.  Protein bound drugs 
ranging from 6% to 99.7% bound were explored to validate microdialysis as a plasma protein 
binding assay.  This technique can also be applied for the in vivo determination of protein bound 
drugs.   
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Chapter 2  
Development of 3-Mercaptapropionic Acid Induced Multiple Seizure Animal Model 
2.1  Background and Significance of Research  
Epilepsy is a neurological disorder that is diagnosed when patients experience two or more 
seizure1.  These seizures may occur as a result of a variety of factors including genetic disposition, 
excitotoxicity, and oxidative stress.  However, the exact mechanism of action of seizure onset is 
unclear.  Several hypotheses have been investigated as possible causes of seizures including 
disruption of pathways and excitatory neuronal emission2-6.   Recent research has demonstrated 
that oxidative stress and the development of epilepsy have a cyclic relationship7-9.  In order to 
better understand this relationship, we must first better understand epilepsy as a whole.   
There are two main types of seizures that patients can experience, global seizures and local 
(focal) seizures.  These categories can be broken down even further to simple local, complex local, 
myoclonic and tonic clonic.  Previous members of the Lunte research lab developed animal models 
for global seizures10 and local seizures11.  However, by definition, patients must experience two or 
more seizures to be diagnosed with epilepsy; therefore, these models are seizure models and not 
true epilepsy models.  Dr. Andrew Mayer performed preliminary experiments toward developing 
an animal model for local epilepsy11.  The research discussed here further investigated and 
developed this model.   
Microdialysis was used to locally dose the hippocampus of a rat with an epileptogenic 
agent, 3-MPA, while simultaneously collecting dialysate for analysis.  The 3-MPA was 
administered at two separate time points within one experiment, simulating two consecutive 
seizure episodes that would define this outcome as fitting the definition of epilepsy.  Various time 
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regimens were explored to investigate the animal’s response to the epileptic agent.  A statistical 
comparison between the first and second seizure event was done to demonstrate the neurochemical 
effect of inducing multiple seizure episodes. 
 
2.1.1 Global Epilepsy – Previous Models 
Global seizures are most commonly associated with epilepsy.  These are also known as 
generalized seizures or tonic-clonic seizures because they affect the electrical activity in both 
hemispheres of the brain.  There are two main phases in these seizures, the tonic phase and the 
clonic phase.  In the tonic phase, the patient loses consciousness, muscles tense, and the body 
become rigid12, 13. This phase typically only lasts for a few seconds before the patient moves into 
the clonic phase.  In the clonic phase, the neuronal misfiring causes the muscular system to rapidly 
contract and release repeatedly; this is known as convulsions.  This phase can last for several 
minutes to hours.  When the patient regains consciousness, nervous exhaustion often occurs, 
patients have difficulty breathing, and at times patients have no memory of the seizure12-14.  
Because these physiological symptoms are so severe, it is easy to diagnose patients with global 
seizures and in many cases the symptoms can be controlled with prescription medication.      
An animal model to simulate global seizures was previously developed in the Lunte Lab 
by Eric Crick15-17.  In this model, a systemic dose of 3-MPA was administered to the intraperitoneal 
cavity, followed by a constant intravenous infusion of 3-MPA to the femoral artery to maintain 
status epilepticus, or global seizure status, for 50 minutes.  3-MPA, glutamate, and GABA were 
all monitored via microdialysis using a probe that had been implanted into the CA3 region of the 
hippocampus (-5.6 A/P, +4.8 L/M, -7.0 D/V versus bregma).  Following the induction of the 
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seizure, there was an increase in extracellular glutamate concentration and a decrease in GABA 
concentration in the dialysate, as was expected based on the mechanism of action of 3-MPA.  Upon 
cessation of the 3-MPA infusion, both neurotransmitters returned to basal levels.  The 
neurochemical response can be seen graphically in Figures 2.1.    
 
2.1.2 Local Epilepsy – Previous Models 
The second main type of seizures that patients can experience is local seizures, or partial 
seizures.  As their name suggests, these seizures only affect the neuronal firing in one region of 
the brain, or in only one hemisphere18, 19.  There are a wide range of symptoms that patients can 
experience from local seizures.  Depending on the brain region being affected, seizures may cause 
sudden mood change, the feeling of déjà-vu, altered sense of hearing, smelling, or seeing, spatial 
distortion, muscle tremors, or hallucinations18, 20.  Because these symptoms are not as severe, many 
times local seizures go undiagnosed and patients do not receive proper treatment.  The specificity 
and unpredictability of these seizures make them difficult to investigate.  For these reasons, a 
model for local seziures was developed by the Lunte group in the hopes of gaining a better 











Figure 2.1: Glutamate and GABA response from systemically induced global seizure15. 
 
Reproduced from the thesis by Dr. Eric Crick.  Bolus systemic dose of 3-Mercaptopropionic acid 
was administered at t=0 and constantly perfused through the femoral vein for 50 minutes 






Figure 2.2: Glutamate and GABA response to locally induced seizure with perfusion of 3-MPA 
through the microdialysis probe. 
Reproduced from the thesis by Dr. Andrew Mayer.  Constant perfusion of 3-MPA through the 




Andrew Meyer directly dosed 3-MPA through the microdialysis probe to the CA1 region of the 
hippocampus (-3.3 A/P, +1.7 L/M, -3.7 D/V versus bregma)21.  To mimic the conditions used by 
Crick, Meyer also constantly perfused the epileptic agent through the probe for 50 minutes (Figure 
2.2).  Once again, an increase in glutamate was observed, however a significantly higher percent 
change from basal occurred with the local dose in comparison to the systemic dose (Figure 2.1 
versus Figure 2.2).  Additionally, an increase in GABA was observed as opposed to the anticipated 
decrease.  These results led us to add a second seizure episode to the model and investigate the 
time between the two seizure inductions to see if varying the time affected the neurochemical 
response.     
 
2.1.3 Hippocampus  
When human patients experience local seizures, the medial temporal network is typically 
affected.  This network includes the hippocampus, amygdala, entorhinal cortex, lateral temporal 
neocortex, medial thalamus, and inferior frontal lobes of the brain22.  The hippocampus is 
commonly associated with the local seizures observed in temporal lobe epilepsy.  The 
hippocampus is part of the limbic system, which is responsible for both short and long-term 
memory and spatial navigation5, 23, 24.  The tissue is curved (typically referred to as seahorse-
shaped) and can be divided into three main regions: the dentate gyrus, the hippocampus proper, 
and the subiculum18.  The hippocampus proper is also known as the Cornu Ammonis (CA) region 
and can be broken down even further into three sub-fields, CA1, CA2, and CA3.  All three regions 
contain pyramidal neurons; however, the size of neurons varies depending on the region.  Neurons 















dense network. The CA3 region contains pyramidal cells and commissural fibers that are 
responsible for transmitting signals to other areas of the hippocampus and the brain25, 26.  
Hippocampal signaling is unidirectional and follows the pathways shown in Figure 2.3.  Because 
the hippocampus is one of the most electrically excitable parts of the brain, it can be easily 
damaged by repeated seizure induction19, 26, 27.  The hippocampus has a highly dense network of 
neurons, and these neurons are constantly being regenerated throughout a lifetime, unless they are 
permanently damaged.  For this reason, the hippocampus has been studied in a wide variety of 
rodent models for neurological disease2, 28, 29. 
 
2.1.4 Amino Acid Neurotransmitters 
Amino acid neurotransmitters are small molecules that transmit information across the 
synapses in the brain.  There are two main categories of amino acid neurotransmitters, inhibitory 
and excitatory. They can either be taken up into the cell through transport carriers or be released 
from the cell via exocytosis30-32.  During exocytosis, the neurotransmitters are released into the 
synapse where they can bind to receptors.  Excitatory amino acids bind to G-protein coupled 
receptors that may contain ion channels and allow positively charged ions such as Na+ to enter the 
cell30, 33.  This results in a depolarization and generates an excitatory response.   Conversely, amino 
acids that open ion channels to allow negatively charged ions flow into the cells are known as 
inhibitory neurotransmitters.  The most common excitatory neurotransmitter is glutamate and the 
most common inhibitory neurotransmitter is GABA34-37.  It is essential to have a balance between 
the two in order to maintain normal polarization in brain neurons.  If there is an imbalance between 
the two, a seizure can occur.  In the present experiments, glutamate and GABA were monitored to 
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determine to what extent 3-MPA is capable of inducing such an imbalance and if this results in a 
seizure38.      
 
2.1.5 Catecholamine Neurotransmitters 
Monoamine or catecholamine neurotransmitters are compounds that contain a catechol 
group with an amino acid.  In the brain, they are synthesized from aromatic amino acids such as 
tyrosine and tryptophan.  Norepinephrine and dopamine function as neuromodulators that regulate 
a variety of neuronal processes such as stress, hormones, and blood circulation by spending a long 
time in the extracellular space39-41.  In these studies, norepinephrine (NE) and dopamine (DA) were 
measured in the brain to investigate their involvement in oxidative stress and seizure induction.  
Additionally, analyzing a class of neurotransmitters that are not directly affected by the epileptic 
agent, the extent of neuronal damage during a seizure can be determined42-44.   
 
2.2 Materials and Methods 
2.2.1 Chemicals and Reagents 
Monobasic sodium phosphate, dibasic sodium phosphate, sodium chloride, potassium 
chloride, magnesium chloride, calcium chloride, disodium ethylenediaminetetraacetate 
(Na2EDTA), 85% o-phosphoric acid, and 0.3-μm alumina powder were purchased from Fisher 
Scientific (Pittsburgh, PA). L-aspartic acid, L-glutamic acid, L-arginine, L-alanine, γ-
aminobutyric acid, 3-mercaptopropionic acid, ammonium acetate, 1-octanesulfonic acid, HPLC-
grade methanol, and HPLC-grade tetrahydrofuran were purchased from Sigma-Aldrich (St. Louis, 
48 
 
MO).  ARC/ARG3.1 Antibody was purchased from Novus Biologics (Littleton, CO) and Anti-
Synaptophysin antibody was purchased from Abcam (Cambridge, MA). Ketamine HCl was 
obtained from Fort Dodge Animal Health (Fort Dodge, IA). Xylazine was obtained from Lloyd 
Laboratories (Shenandoah, IA).  All solutions in water were prepared with 18.2-MΩ distilled, 
deionized water (Labconco, Kansas City, MO).  Artificial cerebral spinal fluid (aCSF) was 
prepared in house and sterile filtered before use. (145 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2, 
1.2 mM CaCl2, 0.45 mM NaH2PO4, and 2.33 mM Na2HPO4). 
 
2.2.2 Liquid Chromatography-Fluorescence Detection 
A liquid chromatographic system with fluorescence detection was used for the analysis of the 
amino acid neurotransmitters in the microdialysis samples.  The method was adapted from Shah 
et al.45.  The system consisted of two Shimadzu LC-10ADvp pumps, a 100 μL Shimadzu mixer, 
and a Rheodyne 9725i PEEK sample injector connected to a Phenomenex Synergi 4-μm Hydro-
RP column (150 × 2.0 mm, Phenomenex, Torrance, CA) with a Phenomenex C18 guard cartridge. 
The binary gradient was controlled by a Shimadzu SCL-10vp system controller. Mobile phase A 
was a 95% 50 mM ammonium acetate buffer:5% THF (v:v), pH 6.4.  Mobile phase B was 100% 
methanol. The gradient was as follows: 1-6 min, 45-60% B; 6-9 min, 60% B; 9-11.5 min, 60-90% 
B; 11.5-12 min, 90-45% B; 12-15 min, 45% B.  The Shimadzu 10AXL fluorescence detector was 



























Figure 2.5: Dual electrode series configuration for electrochemical detection of catecholamines. 
Working Electrode 1: +0.75V, Working Electrode 2:  -0.20V vs. Ag/AgCl reference electrode  
  
WE 1(+)   WE 2(-)
R    O   O R
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2.2.3 Derivatization Mechanism   
Since the amino acids of interest are not naturally fluorescent, derivatization was carried 
out prior to sample analysis.  The primary amines were derivatized with naphthalene-2,3-
dicarboxyaldehyde (NDA) following the reaction in Figure 2.4 described by De Montigny46. 
Briefly, 1.0 μL of 500-mM borate with 87 mM CN- (100:20 v:v) and 1.0 μL of 3 mM NDA in a 
methanol:water solution (50:50, v:v) was added to 3 μL of microdialysate.  The samples were 
allowed to react for 30 minutes in the dark.  After the derivatization was complete, 4.0 μL of the 
sample was injected for analysis.  Samples are stable for up to 12 hours, however, they were 
analyzed as soon as possible to prevent any possible degradation.   
 
2.2.4 Liquid Chromatography-Electrochemical Detection  
A liquid chromatographic system with electrochemical detection was used for the analysis 
of the catecholamine neurotransmitters dopamine and norepinephrine in brain microdialysate.  The 
system consisted of a Shimadzu LC-20AD pump, a Rheodyne 9725i PEEK sample injector, and 
an LC-4C potentiostat (Bioanalytical Systems, West Lafayette, IN) with an Agilent ZORBAX 3.5-
μm SB-C18 column (1 × 50 mm, Agilent Technologies, Santa Clara, CA).  The mobile phase was 
adapted from Stenken et al. and consisted of a phosphate buffer with methanol (90:10, v:v)47, 48. 
Specifically, 100 mM NaH2PO4, 2 mM Na2EDTA, and 0.75 mM SOS, adjusted to pH 3.5 with 
85% o-phosphoric acid. 
Electrochemical detection was performed in series using the glassy carbon working 
electrode set-up shown in Figure 2.5.  Preparation and use of the electrodes have been described 
previously49, 50.  Briefly, a 3 mm glassy carbon electrode embedded in a PEEK block (Bioanalytical 
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Systems, West Lafayette, IN) was polished with various grit size diamond polish (Bioanalytical 
Systems, West Lafayette, IN) followed by 0.3-μm alumina powder. The electrode was then rinsed 
with methanol and water.  The surface of the electrode was carefully dried with a KimWipe and 
placed into the electrochemical flow cell.  The electrode was allowed to equilibrate with the mobile 
phase and charging current for a minimum of one hour after applying the potential.  The detection 
of the catecholamine neurotransmitters were observed at working electrode 1 at an oxidation 
potential of +750 mV versus an Ag/AgCl reference electrode.  The data were collected at 10 Hz 
with a range of 10 nA and processed using a Chrom&Spec chromatography data system 
(Ampersand International, Beachwood, OH). 
 
2.2.5 Determination of Neuronal Activation 
Physiological recordings such as electrocorticography (ECoG) recordings may be used to 
measure the changes in neuronal activity associated with seizures.  Electrocorticography, or ECoG, 
recordings are a type of electrophysiological monitoring in which electrodes are placed directly on 
the exposed surface of the brain51.  Small holes are drilled into the skull so that the electrodes can 
make contact with the cortex.  Dr. Meyer noticed that with the systemic dosing of the epileptic 
agent 3-MPA, changes in electrical activity were observed.  This indicates that the animal is 
experiencing a global seizure because the entire brain is being affected.  With locally induced 
seizures, only a minimal change in electrical activity was observed using the ECoG recordings in 
his studies.  According to his analysis, this was not enough to confirm seizure activity.  Examples 
of both systemic and local dosing ECoG recordings taken by Dr. Meyer can be seen in Figure 







          
 
Figure 2.6: Sample electrocorticographs from both systemic and locally induced seizures. 
Reproduced by the thesis by Dr. Meyer11 
Systemic Dosing  
Local Dosing  
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by the local dosing, there is not a large enough change in electrical activity to be detected by the 
ECoG electrodes.  In order to verify that the local perfusion of 3-MPA was in fact inducing 
seizures, we chose to use immunohistochemical staining to measure the amount of neuronal 
activation.    
 
2.2.5.1 ARC Staining 
Activity-regulated cytoskeleton-associated protein (ARC) is a marker for synaptic 
activation and synaptic plasticity.  ARC is part of a rapidly activated class of genes that are 
categorized by their ability to be transcribed in the presence of protein synthesis inhibitors52, 53.  
ARC is localized in activated synaptic sites dependent on glutamate-NMDA receptors.  The 
presence of newly transcribed protein signifies neuronal activation and plasticity.  ARC regulates 
the endocytosis of AMPA receptors.  AMPA receptors are glutamate receptors that mediate fast 
synaptic transmission in the central nervous system.  By quantifying ARC, we are able to quantify 
the amount of glutamate-driven synaptic activity, in this case representing a seizure.  ARC is 
localized to the synapses, making it easy to stain using antibodies and therefore quantify.  In order 
to confirm that the local perfusion of the 3-MPA led to neuronal activation and synaptic 
transcription, animals were sacrificed after 15 minutes of the start of 3-MPA perfusion, brains were 
harvested for immunohistochemical staining, described in detail later.    
 
2.2.5.2 Synaptophysin  
Synaptophysin is a synaptic vesicle glycoprotein that is present in neuronal cells and all 
other cells involved in synaptic transmission54, 55.  Its exact function is not known; however, 
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knockout studies in mice show behavioral changes, specifically dealing with spatial learning.  Its 
presence at the synapse allows for immunostaining which can be used for quantification of total 
synapses.  Antibodies for both ARC and synaptophysin were used to quantify both total and 
activated synapses to determine what percent of synapses have been activated.  Further explanation 
of tissue staining protocols as well as quantitative results are describe later in this chapter.   
 
2.3 Surgical Procedures  
2.3.1  Animal and Instrumentation Preparation  
Surgical tools were sterilized using ROCCAL® prior to every experiment.  Because these 
were not survival surgeries, autoclave sterilization was not necessary.  Male Wistar Rats weighing 
300-450 grams, purchased from Charles River (Charles River Laboratories, Wilmington, MA) or 
Harlan (Harlan Laboratories, Indianapolis, Indiana) were used in this study.   Rats were housed 
communally with free access to food and water until the time of the study.  Rats were placed in an 
isoflurane chamber and pre-anesthetized via isoflurane inhalation for 5 minutes.  The anesthetic 
cocktail of ketamine(80mg/kg)/xylazine(10mg/kg) was administered I.P. and allowed to take 
effect.  Once the rat was fully anesthetized via, the hair on the skull was shaved as closely as 
possible.  Booster doses of ketamine (40 mg/kg) were administered as needed to maintain adequate 
anesthesia. The animal's body temperature was maintained at approximately 37 °C using a 
PhysioSuite automatic heating unit (Kent Scientific Corporation, Torrington, Connecticut).  All 
animal experiments were done using approved animal use protocols adhering to IACUC 




2.3.2 Microdialysis Brain Probe Implantation 
Once the rat was fully anesthetized, it was then placed in the stereotaxic frame using the 
ear bars and incisor bar.  The skull was made level and centered within the frame.  Once the rat 
was securely in place, an incision approximately 3 cm in length was made in the midline of the 
skull using a 10 blade scalpel.  Four tissue clamps were used to hold the skin to the side, and excess 
tissue was removed using cotton tip applicators.  Once the skull was removed of excess tissue and 
blood, the bregma coordinates were determined.  The appropriate stereotaxic coordinates were 
calculated for the area of interest, the hippocampus (posterior 5.6 mm, lateral +4.8 mm, and ventral 
5.0 mm).  Two 1 mm holes were drilled arbitrarily around the desired probe location and anchor 
screws were inserted to serve as stability for the cannula.  Next, a 3 mm hole was drilled at the 
calculated probe site.  Once the hole had been drilled, the guide cannula was lowered to the 
appropriate depth and fixed to the skull with dental cement, covering the anchor screws.  After the 
dental cement solidified, the dummy probe was removed from the cannula and replaced with a 
CMA 12 microdialysis probe, with a 2 mm PAES membrane length. The probe was perfused with 
aCSF/3-MPA for the duration of the experiment.  The rat was maintained under anesthesia for the 
duration of the experiment using 40-50mg/kg supplemental does of ketamine injected I.P. or I.M.  
At the termination of the experiment, the rat was euthanized using isoflurane overdose followed 
by decapitation and the brain was harvested for histological analysis. 
 
2.4 Experimental Design  
Post operatively, animals were allowed to recover for one hour, during which time aCSF 
was constantly perfused through the microdialysis probe at a flow rate of 1.0 μL/min with a 
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CMA/100 microinjection pump (Harvard Apparatus, Holliston, Massachusetts).  After a 60 minute 
recovery period, aCSF was perfused for one hour and collected in ten minute intervals to serve as 
basal level samples.  After the basal collection, a solution of 10 mM 3-MPA in aCSF was 
administered through the probe at a rate of 1.0 μL/min.   For all experiments, samples were 
collected in ten minute intervals. 
 
2.4.1 Immunohistochemical Staining  
A set of 3 dosed animals and 3 control animals were used for immunochemical staining 
with both ARC and Synaptophysin antibodies.  The surgical procedure and probe implantation 
were the same as describe above.  For the dosed animals, after basal collection, 10 mM 3-MPA 
was perfused through the probe for 15 minutes to ensure neuronal activation.  For the control 
experiments, the animal was only administered aCSF but was sacrificed at the same time point as 
the dosed animal.  One control and one dosed animal were performed on the same day to reduce 
any experimental variability.  The animals were sacrificed and the brain was harvested.  Brains 
were cut into three equal sections, rostral to caudal, using a razor blade, and ensuring not to cut 
through the hippocampus.  Each section was placed in 4% paraformaldehyde in phosphate buffered 
saline (PBS) until solidified, approximately one week.  The tissues were then preserved in 30% 
sucrose-PBS solution and allowed to become saturated, signified by the flotation of the tissues.  
Once saturated, the middle section containing the hippocampus was rinsed with PBS.  
Hippocampal-containing sections were then flash-frozen using liquid nitrogen for 30 seconds then 
placed on dry ice.  The sections were fixed to chilled cryostat platforms using OTC compound.  
The fixed sections were allowed to equilibrate to -40 °C for approximately 45 minutes and then to 
-20 °C for approximately 30 minutes.  Sections were cut in 20 µm thickness and placed in 2 mM 
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EDTA PBS buffer in 12-well plates.  Samples were stored at 4°C until they were ready to be 
stained using antibodies.   
Three sections from each rat were selected to be stained and fixed for imaging.  To stain 
the sections with the ARC and Synaptophysin antibodies, the sections were permeabilized with 
0.2% Triton X-100 for 10 minutes at room temperature.  Sections were then rinsed with PBS to 
remove any excess detergent.  A few drops of Image-IT signal enhancer was added to the wells, 
and then the sections were allowed to incubate for 30 minutes in a humid chamber.  Sections were 
once again rinsed and then placed in 3% gelatin-PBS solution to solidify the slices.    The anti-
ARC antibody was diluted 1:200 in PBS and the anti-Synaptophysin was diluted 1:250 in PBS.  
500 µL of each antibody solution was added to each well and allowed to incubate overnight at 
4°C.  Slices were rinsed with PBS to remove excess antibody.  Secondary antibodies of goat anti-
rabbit and rat anti-mouse were diluted 1:500 in PBS and added to each well for the labeling of 
ARC and synaptophysin, respectively.  Sections were incubated for 2 hours at 37°C.  Finally, the 
sections were rinsed to remove any excess secondary antibody and were mounted to glass slides 
using 70% glycerol-PBS solution.  The slides were imaged using a Leica SPE2 confocal 
microscope.   
 
2.4.2 Animal Experiments – Induction of Two Seizures 
In order to replicate the preliminary studies done by Dr. Andrew Meyer, experiments 
involved the induction of two 30 minute local seizures with 40 minutes between seizure inductions.  
A 30 minute local seizure was induced by perfusing 10 mM 3-MPA through the probe directly 
into the hippocampus.  The rat was allowed to recover for a period 40, 60, or 180 minutes after the 
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3-MPA perfusion stopped, during which time blank aCSF was perfused through the probe.  A 
second 30 minute local seizure stimulation was then induced and aCSF was perfused for one hour 
post second perfusion of 3-MPA.      
 
2.4.2.1 Control Experiments 
In order to confirm that the neurochemical response being observed was due to the epileptic 
agent and not the surgical procedure or the anesthetic agent, control experiments were performed.  
All experimental manipulations done in the seizure experiments were replicated in the control 
experiments, the only difference being the epileptic agent was not administered and instead 
replaced with perfusion of blank aCSF. 
 
2.5 Results and Discussion  
The goal of this research was to development of a rat model for locally induced epilepsy by 
inducing two seizure episodes within one experiment.  Because we were unable to measure seizure 
activity through ECoG monitoring, the seizure induction was confirmed with 
immunohistochemical staining using ARC and Synaptophysin to measure neuronal activation.  
  
2.5.1  Immunohistochemical Staining Results  
Images of both CA1 and CA3 regions of all 18 sections were taken.  Examples images are 
shown in Figure 2.7.  Average pixel density counts for both ARC and Synaptophysin staining were 
made using Leica software for the CA1 and CA3 regions of both control and dosed animals (Table 
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2.1 and 2.2).   There was 49% more neuronal activation in the dosed experiments than in the control 
experiments in the CA1 region and 66% more activation in the CA3 region, quantified by the ARC 
expression.  The synaptophysin expression was essentially the same for both dosed and control 
experiments in all regions.  This was expected.  The Synaptophysin quantified total synapses which 
should not change between dosed versus control.  Likewise, there was minimal difference in both 
ARC and Synaptophysin expression on the contralateral side of the brain in the dosed versus the 
control.  This is to be expected because in both the dosed and control experiments no perturbation 
was experienced on the contralateral side of the brain.   T-tests were performed on this data 
comparing the dosed versus the control in both the CA1 and CA3, producing a p value of 0.08 and 
0.03 respectively, making the difference in neuronal activation significantly different.  The 
statistically significant change in neuronal activation as a result of the 3-MPA dose confirms that 
that the neurons were being activated, signifying seizure induction.    
 
2.5.2 Multiple Dosing Results  
Control experiment data is included in the corresponding time interval graphs.  The yellow 
and black plots on Figures 2.8-2.10 represent the glutamate and GABA data for the control 
animals.  All three experimental conditions show no significant change in glutamate or GABA for 
the controls, meaning the experimental and surgical procedures were not the cause of neurological 





Figure 2.7: Example confocal microscopy images of hippocampal slices taken after ARC (red) 
and Synaptophysin (green) staining  
Stratum oriens (SO), stratum pyramidale (SP), and stratum radiatum (SR) regions are labeled 






CA 1 CA 3 
Dosed Control Dosed Control 
Ipsilateral 
(pixel density) 
41 ± 5 21 ± 3 91 ± 8 33 ± 5 
Contralateral 
(pixel density) 
29 ± 3 21 ± 4 44 ± 3 37 ± 3 
 
Table 2.1: Comparison of pixel density values for ARC staining from CA1 vs. CA3 regions for 
dosed and control animals.  Numbers represent raw pixel density counts taken from the LAS data 




CA 1 CA 3 
Dosed Control Dosed Control 
Ipsilateral 
(pixel density) 
25 ± 6 26 ± 2 37 ± 5 34 ± 3 
Contralateral 
(pixel density) 
24 ± 5 26 ± 4 36 ± 3 40 ± 4 
 
Table 2.2: Comparison of pixel density values for Synaptophysin staining from CA1 vs. CA3 
regions for dosed and control animals Numbers represent raw pixel density counts taken from the 









Figure 2.8: Change in glutamate and GABA concentrations over time following delivery of 10 
































Figure 2.9: Change in glutamate and GABA concentrations following delivery of 10 mM 3-






























Figure 2.10: Change in glutamate and GABA concentration following delivery of 10 mM 3-



























When only 40 minutes recovery time was allowed between dosing with epileptic agent, 
basal levels of glutamate and GABA were not reestablished before the second seizure induction.  
This indicates that at the level of neurochemicals released, there were not two separate seizure 
stimulations (Figure 2.8).  In order to ensure that there were two separate seizure events, time 
between seizure inductions was varied to determine the recovery time necessary for glutamate and 
GABA to return to basal levels prior to the second seizure induction (Figures 2.9, 2.10).  Glutamate 
and GABA concentrations returned to basal levels at approximately 150 minutes after the end of 
the first seizure induction.  This return to initial baseline signifies that each seizure induction was 
a separate episode and that two seizures are induced within one experiment, thereby developing 
the equivalent of an animal model for local epilepsy.   
In all three experiments, a significant attenuation of extracellular glutamate was observed 
during the second seizure episode even though the same concentration of 3-MPA was administered 
for the same length of time to induce each seizure (Figures 2.8-2.10).  By extending the time 
between seizures, more time was available for glutamate recovery after the induction of the first 
seizure.  Two analyses of the data were done.  The first using the baseline prior to the first seizure 
induction to determine glutamate attenuation observed in the second seizure, and the second 
analysis used the baseline directly before the second seizure to determine the glutamate 
attenuation.  The results of both statistical analyses are discussed below.  Possible causes of this 
decrease in glutamate release include glutamate depletion, desensitization to the epileptic agent, 





2.5.3 Statistical Analysis  
In the first analysis of the data, the baseline established prior to the first seizure was used to 
calculate the percent of basal for both seizures.  In this analysis, a 62 ± 3% decrease in glutamate 
response was observed with the stimulation of the second seizure episode after a 40 minute 
recovery period.  A 59 ± 4% decrease in release after 60 minute recovery period and 80 ± 7% 
decrease in release after 180 minute recovery were also observed.   
In the second analysis of the data, the baseline prior to the first seizure was used to calculate 
the percent of basal for the first seizure and the baseline prior to the second seizure induction was 
used to calculate the percent of basal for the second seizure.  It was necessary to calculate the 
response this way since the glutamate concentration never fully returned to the initial baseline prior 
to the second seizure induction, making the baseline prior to the second seizure significantly 
different than the initial baseline.  In this analysis, a 92 ± 3% decrease in glutamate response was 
observed with the stimulation of the second seizure episode after a 40 minute recovery period.  An 
89 ± 4% decrease in release after 60 minute recovery period and 90 ± 7% decrease in release after 
180 minute recovery were also observed.  When using this analysis, significantly higher 
attenuation in glutamate release is being observed.  This is to be expected since the baseline is 
never fully able to recover prior to the second induction.  The cells do not have time nor nutrients 
to release the same amount of glutamate in both stimulations.  Interestingly, there was not a 
statistically significant difference between the analyses in the 180 minute results, further 
confirming that 180 minutes was enough time for baseline to essentially be reestablished prior to 























Table 2.4: Percent attenuation in glutamate release for each experiment using individual baseline 
for each seizure.
Experimental 
Interval  Attenuation (%) p Value 
40 min 62 ± 3 (N=7) 0.005
*
 
60 min 59 ± 4 (N=5) 0.021
**
 




Interval  Attenuation (%) p Value 
40 min 92 ± 3 (N=7) 0.00042
***
 
60 min 89 ± 4 (N=5) 0.00037
***
 












Figure 2.11: Graphical comparison of glutamate release between first and second seizure 
episodes for each experimental condition. 























To demonstrate statistical significance and determine the difference in neurotransmitter 
response in the first and second seizure episodes, t-tests were performed on all data (Table 2.3 and 
4).  For the first analysis method, the 60 min and 180 min intervals had confidence levels of p<0.05 
and the 40 min interval experiments had a confidence interval of p<0.01. For the second analysis, 
all experiments had a confidence interval of p<0.0005.  This confidence interval implies that 
thereis a significant difference in the glutamate response between the first and second seizure.  
Figure 2.11 graphically represents these differences for each of the time interval.   
 
2.5.4 Glutamate Attenuation Hypotheses  
The initial hypothesis as to the cause of attenuated glutamate release in the second seizure 
that was investigated was glutamate depletion.  During the seizure, the vesicles release glutamate 
into the synaptic cleft.  As can be seen in the above data, glutamate concentrations steadily increase 
and then remain elevated for the duration of the thirty minute seizure.  Once the seizure is over, 
the concentration approaches basal levels again, but the reservoir of glutamate has already been 
depleted.  It is possible that a 60 minute delay was still not enough time after the first seizure for 
the glutamate supply to regenerate, so the time was extended to 180 minutes between seizures56.  
Because such a severe decrease in glutamate release was still observed even after 180 minutes 
recovery time, it is believed that the cells are being starved for nutrients such as glucose and lactate 
that are necessary for the production of glutamate57-59.  A series of experiments to further 
investigate this hypothesis were conducted and are discussed in Chapter 3.    
Desensitization to the epileptic agent could also lead to the attenuated glutamate release.  
Desensitization results when binding of the ligand to a receptor leads to a decrease in the 
effectiveness of the receptor.  When this happens, the receptor is no longer able to allow the release 
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or reuptake of the neurotransmitters.  High concentrations of post-synaptic neurotransmitters can 
act upon the pre-synaptic terminals depressing further release, resulting in an apparent decrease in 
neurochemical response60, 61.  This affects communication between glial cells and neurons.  
Furthermore, if desensitization occurs it can result in excitotoxicity that can result in neuronal 
damage and death.   
Finally, the last hypothesis discussed here is glutamate excitotoxicity.  Unfortunately, 
glutamate excitotoxicity can occur at relatively low concentrations and has been observed with 
extracellular levels of glutamate as low as 2-5 µM62-64.  Cellular swelling and apoptosis have been 
observed with glutamate concentrations around 25 µM and necrosis occurs with concentrations of 
approximately 100 µM extracellular glutamate65, 66.  Excitotoxicity is an important factor to 
consider when studying epilepsy because many times the effects of the excitotoxicity are more 
damaging than the seizures themselves.  Neuronal damage is also a possible cause of the attenuated 
glutamate response.  However, the catecholamine data in Figure 2.12 suggests that there is no 
significant reduction in NE and DA release during the second seizure episode.  Interestingly, there 
was no significant increase in NE during the seizure stimulations, but there was in DA.  In a recent 
study by Rocchetti et al. DA fibers were located and labeled in the CA1 region of the 
hippocampus67.  This could be the reason for the increase in DA with stimulation.  Because there 
was no significant difference in DA release between the two seizure inductions, this leads to the 
conclusion that the dopaminergic neurons are not being severely damaged.  In this study, the GAD 
inhibitor produced such a large increase in glutamate that it is possible that a feedback mechanism 
is occurring, where glutamate itself is acting on the pre-synaptic terminal, thus depressing further 
release of glutamate68-71.  Glutamate concentrations during the seizure stimulation ranged from 5-









Figure 2.12: Change in norepinephrine and dopamine concentrations over time following 

























2.6 Conclusions  
In this chapter, an animal model for locally induced epilepsy was developed by the 
induction of two seizure episodes within the same experiment.  A 40 and 60 minute delay between 
seizures was not sufficient for basal levels of neurotransmitters to be reestablished, meaning these 
were not two separate events.  It required 150 minutes of recovery time after the first seizure before 
basal levels were reestablished.  By allowing 180 minutes of recovery time, the second seizure 
induction was truly a separate event.  Significant attenuation in glutamate release was observed in 
the second seizure induction for all investigated time regimes.  It was originally hypothesized that 
there was not enough time for recovery of glutamate levels, but 180 minutes of recovery should 
have been enough time.  Several hypotheses as to the cause of attenuation have been investigated 
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Chapter 3  
Neurochemical Investigation of Glutamate Depletion and Oxidative Stress Observed in the 
Multiple Seizure Model 
3.1 Background and Significance  
Chapter 2 discussed the development of an animal model for local epilepsy.  By definition, 
epilepsy is diagnosed after the patient experiences two or more seizures.  For this reason, a single 
seizure stimulation is not sufficient to constitute an epileptic model.  Local seizure-like 
stimulations were induced in the CA1 region of the hippocampus for 30 minutes each.  Because 
the same concentration of epileptic agent was administered for the same length of time in each 
episode, it was anticipated that the neurochemical response would be the same in both stimulations.  
Significant attenuation in glutamate response was observed during the second stimulation.  There 
are several hypotheses available as to the cause of the decrease in glutamate release.  This chapter 
discusses the investigation of four of the most likely hypotheses: glutamate depletion by metabolic 
and energy pathways, neuronal protective response, neuronal damage, and the mechanism of 
action of the epileptic agent.    
 
3.1.1 Glutamate Depletion   
The vesicles at the nerve terminals contain different pools of neurotransmitters, including the 
readily releasable pool, the recycling pool and the reserve pool1.  The readily releasable pool is 
located close to the membrane and contains the first group of neurotransmitters to be released into 
the extracellular space, in this case glutamate2.  When stimulation occurs via the epileptic agent, 
the glutamate in the readily releasable pool is quickly released.  Once this pool has been drained, 
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continuous stimulation mobilizes the glutamate in the recycling pool for release.  Only with intense 
stimulation does the glutamate in the reserve pool get released.  In the case of a 30 minute seizure 
stimulation, it is likely that all three pools are mobilized and release all available glutamate into 
the extracellular space.  If this occurs during the first seizure, there may not be enough time or 
nutrients for the glutamate pools to be replenished prior to the second seizure episode3, 4.  This 
could completely deplete the glutamate supply.  We predicted that 180 minutes would be enough 
time for the pools to be replenished, however, attenuation in glutamate release was still observed 
after that time delay (Chapter 2).  For this reason, it was hypothesized that the lack of nutrients 
available to the mitochondria is the cause of the glutamate diminution, specifically glucose and 
lactate.  Once the pools are depleted, glutamate must be synthesized to replenish them through the 
KREBS cycle (Figure 3.1).  The mitochondrial enzyme, glutaminase metabolizes glutamine into 
glutamate.  Additionally, glutamate is taken up by glia to be converted to glutamine, which is then 
released and taken up by neurons to be converted back from glutamine to glutamate.   
Glucose is a key precursor to glutamate synthesis, and therefore adding it to the system would 
enhance glutamate production.  Similarly, when neurons are stressed, glial cells release lactate to 
enhance glutamate synthesis which can lead to potential neuronal damage5, 6.  It is possible that 
the first seizure episode depleted the surrounding glia of lactate, thus diminishing a major source 
of mitochondrial KREBS nutrients. Therefore, lactate supplementation might enhance the energy 



















3.1.2 Neuronal Protective Responses  
Upon extensive stimulation, the brain has a natural tendency to self-preserve neuronal 
structure and function, i.e., neuronal protection10.  The overall goal of the self-preservation is to 
slow the rate of neuronal loss caused by repeated disruption of the system.  While the body does 
this naturally, induced neuroprotection has also recently been explored as a form of treatment for 
neurodegenerative diseases such as traumatic brain injury, Alzheimer’s disease and Huntington’s 
disease11.  The natural neuronal protective response is triggered when imbalances in the brain occur 
as a result of oxidative stress, mitochondrial dysfunction, or excitotoxicity11-14.  Excitotoxicity 
caused by glutamate is the most common cause of neurodegeneration.  When glutamate receptors 
are hyperactivated, the calcium ion channels remain open.  This results in oxidative damage.  The 
induction of a seizure may cause the hyperactivation of glutamate transporters as a form of 
neuronal protection.  Glutamate transporters function to remove glutamate from the synaptic cleft 
to be taken up by neurons and glia.  There are glutamate transporters on both glial cells and neurons 
and they are essential in maintaining the balance of extracellular glutamate and preventing 
excitotoxicity15, 16.  When extracellular glutamate concentrations reach excitotoxic levels, the 
transporters go into overdrive as a neuronal protective response to the stimulant.  They begin to 
take up all and any available glutamate, which could be a reason for the attenuated glutamate 
response in the second seizure episode.  If all extracellular glutamate is taken up by the 
transporters, reduced amounts of glutamate would remain in the extracellular space for collection 





3.1.3 Neuronal Death and Damage 
As mentioned above, high levels of extracellular glutamate can lead to excitotoxicity and 
eventual cell death11,17-19.  Unfortunately, glutamate-induced excitotoxicity can occur at relatively 
low concentrations of extracellular glutamate (2-5 µM)11.  Excitotoxicity-induced cell death is an 
important consideration in seizures because after an initial seizure, the cells become more easily 
excitable due to damage and sensitization, which can lead to subsequent seizures and damage.  
Studies have shown that often the excitotoxicity is more damaging than the seizures 
themselves20,21.  If significant cell death occurs before the induction of the second seizure, then 
there are not enough viable neurons and glial cells available for glutamate release in the second 
seizure induction.   
 
3.1.3.1 Detection of Neuronal Damage 
Propidium iodide (PI) is a fluorescent molecule that intercalates between the bases in DNA22.  
It does not have sequence preference and exhibits a stoichiometric ratio of one PI molecule to 4-5 
base pairs in DNA23.  PI is not able to permeate viable cell membranes and therefore will not stain 
viable cells.  However, if the cell membrane has been damaged, the PI will penetrate and be able 
to reach the nucleus for binding.  This selective permeability allows for PI to be used as a marker 






3.1.4 Other Epileptic Agents   
Various chemical agents may be used to alter the excitatory/inhibitory balance in the brain.  
The biggest benefit to using a chemical stimulation model is that seizure duration and intensity 
can be easily controlled and reproduced.  The work in Chapter 2 utilized the GAD inhibition 
mechanism of action of 3-MPA to develop an animal model for local epilepsy24, 25.  While this 
epileptic agent has been used in previous studies both in this lab and in the literature30-33, it could 
be the cause of the glutamate attenuation being observed during the second stimulation.  
 It is well-known that 3-MPA can damage and kill glial cells34.  Specifically, 3-MPA damages 
ionotripic glutamate receptors such as the N-methyl-D-aspartate receptor35.  These receptors play 
a crucial role in synapse formation and neuronal plasticity.    This damage could be the reason for 
the decreased glutamate in the second seizure episode.  Additionally, the damage to the glial cells 
could result in higher extracellular glutamate concentrations, leading to neuronal damage and 
death. 
Other types of convulsants can act as either agonists or antagonists of either the glutamate or 
GABA receptors26, 27.  Agonists of glutamate receptors open glutamate channels and can lead to 
abnormal electrical discharges.  Two of the most common glutamate receptor agonists are kainic 
acid (KA), which acts on the ionotropic glutamate receptors, and homocysteic acid, which acts on 
the metabotropic glutamate receptors28, 29.  To rule out 3-MPA as the cause of the glutamate 
attenuation, a different epileptic agent with a different mechanism of action was utilized.  Kainic 
acid (KA) is a well-known epileptic agent that activates the kainate glutamate receptors28, 29, 36.  
KA is an agonist for the kainate receptors, the receptors that control Na+ channels responsible for 
producing excitatory postsynaptic potentials.  This hyperactivation of the excitatory responders 
will result in a seizure.   
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3.2 Materials and Methods  
3.2.1 Chemical Reagents  
Glucose, lactate, dihydrokainic acid, and kainic acid were all purchased from Sigma-Aldrich 
(St. Louis, MO).  Propidum iodide was purchased from Abcam (Cambridge, MA). All other 
reagents purchased for use in this study are listed in Chapter 2. 
  
3.2.2 Liquid Chromatography- Fluorescence Detection  
Sample analysis was carried out as described in Chapter 2.  The same analytical systems, 
mobile phases, and sample preparation that was describe in the earlier chapter were implemented 
in this chapter as well.  Because only glutamate diminution was observed, samples were only 
analyzed for amino acid neurotransmitters.  Briefly, 3.0 µL of sample was derivatized following 
the NDA/CN- mechanism describe by De Montigny et. al37.  Derivatized samples were then 
injected on to an LC-Fl system consisting of a reverse phase column, two Shimadzu pumps, and a 
Shimadzu 10A-XL fluorescence detector at an excitation wavelength of 442 nm and an emission 
wavelength of 490 nm.     
 
3.2.3 Surgical Procedures  
Similar to the analytical methods, the same surgical and animal procedures describe in 
Chapter 2, Section 3 were followed for all experiments carried out in this chapter as well.   Male 
Wistar Rats weighing 300-450 grams, purchased from Charles River (Charles River Laboratories, 
Wilmington, MA) or Harlan (Harlan Laboratories, Indianapolis, Indiana) were used in this study.   
Rats were housed communally with free access to food and water until the time of the study.  Rats 
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were anesthetized with a cocktail of ketamine and xylazine and maintained under anesthesia with 
booster doses of ketamine for the duration of the experiment.   
Once the rat was fully anesthetized, it was then placed in the stereotaxic frame, an incision 
made, and the bregma located.  The appropriate stereotaxic coordinates were calculated for the 
CA1 region of the hippocampus (posterior 5.6 mm, lateral +4.8 mm, and ventral 5.0 mm).  Anchor 
screws and the probe were implanted. The probe was perfused with aCSF/3-MPA for the duration 
of the experiment.  At the termination of the experiment, the rat was euthanized using isoflurane 
overdose followed by decapitation and the brain was harvested for histological analysis. 
 
3.3 Experimental Design  
3.3.1 Mitochondrial Starvation  
3.3.1.1 Glucose and Lactate Supplementation  
Both glucose and lactate are important precursors of glutamate that may have been depleted 
during the first seizure, leading to a reduction in intracellular glutamate5, 6, 9, 38, 39.  In this set of 
experiments, either 15 mM glucose or 10 mM lactate was added to the perfusate during the inter-
seizure period to determine whether glutamate depletion following the first episode of seizures 
was caused by a reduction in glutamate synthesis7, 9.  
 
3.3.2 Transporter Pathway  
In another set of experiments the transporter pathway was investigated to determine if a 
neuronal protective response is occurring.  To test this hypothesis, a glutamate transport blocker, 
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1.0 mM dihydrokainic acid, was administered simultaneously through the MD probe with the 
second dose of the epileptic agent40.  Blocking the transporters counteracts this hyperactivation 
and protective response, leaving all available glutamate in the extracellular space to be measured 
via microdialysis sampling.   
 
3.3.3 Neuronal Death and Damage  
To determine the amount of cell death occurring during and after the first seizure, propidium 
iodide (PI) was used to stain slices of the brain tissue to determine cell viability22.  Brain slices 
were stained with PI, and the number of dead (PI-positive) cells were counted.  For the 
histochemical staining experiments, surgical procedures were the same as described above.  
Experiments followed the same protocol as in the 180-min time regime.  Both control and 3-MPA 
dosing experiments were performed for histochemical staining.  Animals were sacrificed 
immediately before the induction of the second seizure stimulation to determine the amount of 
viable cells at that time point.  The brain was harvested and cut into 1 mm thick slices which were 
incubated in aCSF with 10 mM glucose to keep them viable.  Slices were incubated with 1.5 mL 
of 10 µg/mL PI for 30 min at 37 °C.  After the staining was complete, slices were rinsed with aCSF 
and read on a Nikon Eclipse TE2000-S inverted microscope.  Images were captured using a 1X 
objective lens and NIS-Elements software.    
 
3.3.4 Epileptic Agent Mechanism of Action  
To determine if the mechanism of action of 3-MPA is the cause of the glutamate diminution 
or cell damage, preliminary experiments using KA as an epileptic agent as opposed to 3-MPA 
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were done.  The experimental procedures were identical to those previously described above.  Two 
30-minute seizure inductions were made by delivering 500 µM KA in aCSF through the 
microdialysis probe rather than the 3-MPA.  The same 180 minute recovery period with blank 
aCSF was allow between the two inductions.                
 
3.4 Results and Discussion  
3.4.1  Statistical Analysis  
Similar to the statistical analyses performed in Chapter 2, analysis of this data was done 
twice, once using the initial baseline for both seizures, and once using the baselines before each 
individual seizure for calculation.  Numbers obtained from the second set of calculations are 
represented in parentheses below.  Statistical analysis was performed using t-tests that were run 
on each set of experiments to demonstrate if there was a statistically significant difference in 
glutamate response between the two seizure episodes and are shown in Table 3.1 and Table 3.2.  
Graphical representation to summarize the difference in glutamate release between seizure 
episodes one and two for all of the experimental conditions is shown in Figure 3.2.  The error bar 
on the first seizure for the DHK experiments is extremely large because one animal did not 
experience a first seizure.   
 
3.4.2 Transporter Inhibition  
DHK had very little effect on the amount of glutamate released during the second seizure 























Table 3.2: Percent attenuation in glutamate release for each experiment using individual baseline 
for each seizure. 
Medium 
Supplementation   Attenuation (%) p Value 
aCSF 80. ± 7 (N=5) 0.019 
15 mM Glucose 57 ± 3 (N=5) 0.039 
10 mM Lactate 50. ± 4 (N=6) 0.016 
1.0 mM DHK 70. ± 4 (N=5) 0.022 
Medium 
Supplementation   Attenuation (%) p Value 
aCSF 90. ± 7 (N=5) 0.0005 
15 mM Glucose 79 ± 3 (N=5) 0.0007 
10 mM Lactate 19 ± 4 (N=6) 0.28 







                
 
 
Figure 3.2: Graphical comparison of glutamate release between first and second seizure episodes 






























Figure 3.3:  Glutamate transporter inhibition by dihydrokainic acid during second seizure 



























glutamate release was observed during the second seizure-like stimulation, which was less than 
the 80 ± 7% (90 ± 7 %) observed in experiments performed in the absence of DHK.  However, 
this was not a statistically significant improvement compared to control, leading us to believe that 
the increase in glutamate reuptake is most likely not the mechanism responsible for the diminution 
of glutamate release during the second seizure episode.   
 
3.4.3 Mitochondrial Starvation  
Another set of experiments involved supplementing the perfusate with 15 mM glucose between 
the two seizure events (Figure 3.4).  Under these conditions, a 23 ± 3% (11 ± 3%) increase in 
extracellular glutamate concentrations was observed during the second episode compared to the 
180-min control experiment without glucose.  However, these glutamate levels were still 
significantly attenuated compared to those in the first seizure, an indication that additional factors 
were possibly affecting glutamate production.   
Interestingly, there was a 30 ± 4% (71 ± 4%) increase in glutamate release observed during the 
second seizure episode with lactate supplementation compared to 180-min control experiments 
without lactate (Figure 3.5).  According to the first calculation, an attenuation in glutamate release 
was still observed during the second episode when compared with the first.  However, when the 
true baseline is used for the second seizure induction, there is only at 19 ± 4% attenuation in 
glutamate release in the second seizure episode.  After a t-test analysis comparing the first seizure 
to the second seizure, there was no statistically significant difference in the glutamate release 
between seizures when the perfusate was supplemented with lactate (p=0.28).  This increase can 
most likely be explained by the direct connection of lactate to the KREBS cycle.  During 


































































encourage the KREBS cycle.  By flooding the system with supplemental lactate, this process can 
occur quicker.  The conversion of lactate to glutamate is a much faster process than glucose to 
glutamate.  Lactate can directly supplement the production of α-ketoglutarate to increase 
glutamate.  The keto-acids are transported out of the mitochondria to be used for glutamate 
synthesis which can then be release from the vesicles or by cell damage.     
It is apparent from both the glucose and lactate experiments that the surrounding glial cells 
were being depleted of the nutrients needed for glutamate biosynthesis.  Supplementing the 
perfusate with lactate yielded a significant increase in glutamate release in the second seizure 
episode.  A slight increase in glutamate release was observed when the perfusate was supplemented 
with glucose.  Both of these observations confirm mitochondrial starvation, however, the fact that 
the glutamate concentration never reached the same level in the second seizure suggests that other 
factors must also be affecting glutamate production or release.   
 
3.4.4 Neuronal Death and Damage  
Figure 3.6 shows PI-stained histological slices representing the contralateral and ipsilateral 
sections of a control hippocampus and a hippocampus subjected to the administration of 3-MPA.  
There was statistically significantly more damage to the ipsilateral side of dosed rats compared to 
that of the control rats (Table 3.3).  It was determined that 37 ± 8% more CA1 and 30 ± 9% more 
CA3 cells in the ipsilateral hippocampus had died in the dosed rats than in the control rats prior to 
the second seizure episode.  No significant difference in damage was observed in the contralateral 
side.  Additionally, there was overall more damage in the ipsilateral side of the hippocampus for 




Figure 3.6: Propidium iodide staining of hippocampal slices after the first seizure induction and 
180-min recovery period. 





Damage Diff (%) 
N=6 p Value 
CA1 39 ± 1 0.056*** 
























































CA3 Region  
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This is to be expected because the probe was implanted on the ipsilateral side and the contralateral 
side remained undisturbed in both dosed and control rats.  From these experiments, it can be 
concluded that there is substantial neuronal death during the first seizure, which would lead to a 
significant reduction in glutamate release during the second seizure episode. However, this 
reduction was not the sole cause of glutamate attenuation during the second seizure episode, since 
an increase in glutamate release with both lactate- and glucose-supplemented systems was 
observed using this same seizure model. 
 
3.4.5 Kainic Acid  
The CA1 region of the hippocampus is not as rich in kainate receptors as other regions of the 
hippocampus, therefore using KA as an epileptic agent in this region would be difficult to get the 
same level of excitation as that observed with the 3-MPA.  Figure 3.8 shows preliminary results 
for the induction of successive seizure episodes, 180 min apart, within the same experiment using 
KA as the epileptic agent instead of the 3-MPA.  An opposite trend was observed using KA 
compared with 3-MPA.  There was a greater glutamate release in the second induction, compared 
to the first induction.  It is possible that because there are not very many kainate receptors in CA1, 
the few that are there are becoming sensitized to the epileptic agent.  Sensitization refers to an 
increase in response caused by repeated exposure to a stimulus.  Similar to the kindling effect for 
inducing seizures, the animal becomes sensitized to the epileptic agent following the first 
application and experiences seizures, or more severe seizures, during the second application of 
KA.  The different trend could also be explain by the different mechanisms of action for seizure 


































at any concrete conclusions regarding the meaning of these results, however, it would be beneficial 
to add additional seizure episodes to this model to determine if the increase in extracellular 
glutamate release is compounded with additional seizure episodes.  Furthermore, a brain region in 
which kainate receptors are more highly expressed, such as the CA3 region, should also be studied.    
   
3.5 Conclusions  
Based on the results presented here, it is proposed that deficits of glutamate biosynthesis 
leading to glutamate depletion and cell/neuronal damage/death are the major contributors to the 
diminution in glutamate release during the second period of seizures induced by 3-MPA.  
Supplementing the perfusate with lactate proved to have a significant effect on the biosynthesis of 
glutamate, most likely by encouraging the KREBS cycle.  In the future, other epileptic agents 
should be investigated to determine the specificity of action of 3-MPA-induced seizures in causing 
depletion of glutamate levels and neuronal damage.   More seizures should be added to the model 
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Chapter 4  
Effect of Glutathione Upregulation and Downregulation on Oxidative Damage 
4.1 Background and Significance  
A major secondary effect of seizures is oxidative stress that occurs when there is an 
imbalance in the body’s endogenous antioxidants and reactive oxygen and nitrogen species (ROS 
and RNS)1-4.  Several rodent models have been developed to study the secondary effect of 
oxidative damage associated with epilepsy5.  The body can scavenge ROS both enzymatically, for 
example through superoxide dismutase (SOD), or glutathione peroxidase (GPx) or 
nonenzymatically, through compounds like antioxidants 5.   
Glutathione (GSH) is one of the most prominent natural antioxidants in the brain6.  GSH 
contains a thiol group that can act as a reducing agent to neutralize ROS.  When GSH is oxidized, 
it can readily react with another oxidized GSH to form stable glutathione disulfide (GSSG).  This 
reaction is catalyzed by GPx.  It is hypothesized that higher levels of GSH in the brain would 
reduce the amount of oxidative damage by neutralizing the ROS7, 8.  Similarly, decreased GSH 
would lead to an increase in oxidative damage.  The brain accounts for nearly 20% of the aerobic 
metabolism for the body.  It is the organ that consumes the highest amount of oxygen and is rich 
in polyunsaturated fatty acids5. These factors make brain cells highly susceptible to ROS-induced 
damage, specifically lipid peroxidation.     
Arachidonic acid (ARA) is a fatty acid that is responsible for maintaining neurological 
health and hippocampal cell membrane structure9.  It can help protect the brain from oxidative 
damage by activating lipid receptors10, 11.  When cell membranes become damaged during 
oxidative stress, ARA undergoes lipid peroxidation, producing fatty acid radicals and eventually 
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stable end products, like malondialdehyde (MDA).  Previous research in the Lunte lab by Dr. Carl 
Cooley demonstrated a significant increase in MDA production with the induction of a local 
seizure using 3-MPA12.  His results are shown in Figure 4.1.  Increasing doses of 3-MPA resulted 
in an increase in extracellular MDA production.  As discussed in Chapter 3 of this thesis, cell 
damage occured with seizure induction, which was confirmed with PI staining.  When a significant 
amount of stress occurs to the cells, the ARA cannot counteract the ROS and gets broken down, 
producing MDA, which can be used as a quantitative biomarker of seizure induced oxidative 
damage.   In this research, seizures were locally induced to one region of the brain.  Because the 
seizure induction was so localized, the imbalance was focused to a small region, leading to 
concentrated neurotoxicity.  This localized imbalance and subsequent neurotoxicity can affect a 
multitude of oxidative pathways.   It is evident that there is a correlation between seizures and 
oxidative damage; however, the specific pathways and brain regions that account for this damage 
are still unclear.  
This chapter describes a study in which the amount of an antioxidant, GSH, was modulated 
prior to the induction of seizures.  Extracellular MDA and GSH levels were measured before, 
during, and after the induction of a single seizure to determine the role of GSH on seizure induced 
oxidative damage.  Control experiments were performed by measuring basal concentrations of 
GSH and MDA before the induction of a seizure.  GSH synthesis was then upregulated to see if 
an increase in GSH leads to a decrease in MDA, signifying a decrease in oxidative damage.  
Conversely, GSH synthesis was also downregulated to determine if a decrease in antioxidants 








Figure 4.1: Extracellular MDA concentration versus time from CA1 region of the hippocampus 
as determined by microdialysis sampling. 
The red bar represents the period when 3-MPA was being perfused through the probe, starting at 
time zero, ending at time 50.  Two concentrations were tested, 10mM (blue plot) (n=5), and 1 
mM (pink plot) (n=3).  (* p<0.001 for 10 mM perfusion t-test) 




4.1.1 Glutathione as an Antioxidant   
The body has a series of defense mechanisms to protect itself from oxidative stress. 
Glutathione (GSH) is a natural antioxidant tripeptide containing glutamate, cysteine, and glycine.  
It functions as a reducing agent and ROS scavenger6, 13, 14.  GSH is present in the millimolar range 
intracellularly and the micromolar range extracellularly5.  Under normal physiologic conditions, 
GSH is oxidized by hydrogen peroxide in the presence of GPx to form GSSG15.  GSH plays a key 
role in the body’s defense against oxidative stress through two mechanisms: scavenging free 
radicals and acting as a cofactor for oxygen damage-protecting enzymes.   GSSG can be reduced 
back to GSH by glutathione reductase using NADPH as an electron donor16.  Because GSH exists 
in both the oxidized and reduced forms, it can serve as a redox agent to prevent oxidative damage8.  
It has been reported that, during a seizure, there is a decrease in glutathione reductase enzymatic 
activity5.  When this happens, there is a decrease in GSH and an increase in GSSG.  Less GSH 
available means less antioxidants to neutralize the ROS, leading to further damage and 
hyperexcitabilty17.  This cycle continues until the damage is irreparable.   Therefore, in this chapter,  
it is hypothesized that neurotoxicity, specifically seizure induced oxidative damage, can be 
modulated by either upregulating or downregulating the amount of GSH.  Encouraging GSH 
synthesis or GPx activity may have mitigating effects for seizure induced oxidative damage.    
 
4.1.2 Biomarkers of Oxidative Damage  
The most direct way to measure the amount of oxidative stress is to quantify the amount 
of ROS and RNS in the body1, 18, 19.  Various pathways and resulting damage of oxidative stress 
are shown in Figure 4.2.  Superoxide and hydroxyl radicals are the most common ROS.  Half-lives 
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of these free radicals are typically between 10-6 to 10-9 seconds with basal levels of 90 nM for 
superoxide to 60 nM for hydroxyl radical, so it is important to find other, more stable markers to 
measure the amount of oxidative damage occurring to the body.   
 
4.1.2.1 Lipid Peroxidation  
Lipid peroxidation occurs when oxidative free radicals react with lipids in the body.  
Phospholipase A2 is responsible for the hydrolysis of phospholipids, which causes the release of 
arachidonic acid from neural membranes during oxidative stress10-12.  When membrane lipids are 
oxidized by free radicals, their structure changes and the cell is damaged.  There are three steps to 
this process: initiation, propagation, and termination.  These end with the formation of lipid 
oxidation products (LOPs) that are shown in Figure 4.3.   In the initiation step, a fatty acid radical 
is produced by the reaction of fatty acids with ROS. These fatty acid radicals are unstable and 
therefore quickly react with oxygen to produce peroxyl-fatty acid radicals.  These radicals are also 
highly unstable and readily react with other free fatty acids to produce additional radicals, lipid 
peroxides, or cyclic peroxides20, 21.  This propagation cycle continues as new fatty acid radicals are 
produced and continue to react with one another.  Finally, when two fatty acid radicals react with 
each other, they produce an unreactive non-radical species in a process known as termination.  This 
only happens when the radical species concentration is high enough to encourage the collision of 
two radicals rather than a radical with a non-radical.  After termination occurs, lipid 
hydroperoxides are formed that quickly decompose into more stable compounds such as 
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4.1.2.2 Malondialdehyde  
As stated above, lipid peroxidation leads to the formation of lipid hydroperoxides and 
bicyclic endoperoxides.  These peroxides breakdown further into secondary products like acrolein, 
HNE and MDA.  It was shown in Chapter 3 that cell damage was occurring from the propidium 
iodide staining.  In these studies, MDA was selected as the biomarker to quantify the amount of 
oxidative stress induced lipid peroxidation.  MDA is a more stable biomarker for the determination 
of lipid peroxidation induced oxidative damage than acrolein or HNE.  In this study, MDA was 
quantified using a commercially available fluorescence assay.  Thiobarbituric acid (TBA) reacts 
with MDA to form a fluorescent TBA-MDA adduct that can be quantitated 
spectrophotometrically.    
 
4.1.3 Upregulation and Downregulation of Glutathione  
4.1.3.1 Buthionine Sulfoximine – Downregulation of GSH 
Because GSH functions as a reducing agent and ROS scavenger, depletion of GSH should 
make the cells more susceptible to the effects of oxidative damage.  Buthionine sulfoximine (BSO) 
has been shown to function as an inhibitor of ɣ-glutamylcysteine synthase, the rate-limiting 
enzyme in GSH synthesis24.  A study by Vanella et al. has shown that the intravenous dosing of 
BSO depletes total GSH in the striatum by up to 59% within 24 hours of the dose14, 25.  BSO takes 
24 hours to take full effect and remains in the system, depleting GSH for up to 48 hours.   
Furthermore, BSO does not affect other biological thiols, keeping the rest of the system essentially 
unaltered.  By administering BSO prior to the induction of a seizure, the amount of GSH would be 
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downregulated.  It was anticipated that by decreasing the amount of the antioxidant available there 
would be an increase in the amount of observed oxidative damage.   
 
4.1.3.2 ɣ-Glutamylcysteine Ethyl Ester – Upregulation of GSH  
An important precursor to GSH, ɣ-glutamylcysteine is the rate limiting substrate in GSH 
biosynthesis26.  It is anticipated that, by increasing the amount of natural antioxidant GSH in the 
system prior to seizure induction, the brain would suffer less oxidative damage.  Studies have 
shown that the administration of ɣ-glutamylcysteine ethyl ester increases the total levels of ɣ-
glutamylcysteine by protecting the substrate for GSH synthesis27.  The conversion from ɣ-
glutamylcysteine to GSH goes to completion quickly.    By administering the precursor to GSH 
synthesis, there should be an increase in total GSH in the system and a reduction in oxidative 
damage.        
 
4.2 Materials and Methods  
4.2.1 abcam© GSH/GSSG Ratio Detection Assay Kit (Fluorometric Green) 
Samples were analyzed for GSH using a commercially available, abcam© GSH/GSSG Ratio 
Detection Assay Kit, purchased from abcam© (Cambridge, MA).   Samples and standards were 
prepared according to the user guide.  The derivatization reagent was Thiol Green Indicator.  
Unfortunately, the exact structure of this compound is proprietary, and is therefore not reported in 
the literature.  The molecular weight of the reagent is 419 Da and it contains a fluorophore masked 
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by a quencher. Upon reaction with a thiol, the quencher is released, increasing the fluorescence 
intensity (This information was provided by Dr. Paul, the Scientific Support Manager at abcam©)      
  Because microdialysis produces essentially protein-free samples, no additional sample 
clean-up or preparation was required prior to the derivatization of the real samples.  According to 
the kit instructions for low volume sample analysis, 25 µL of sample or standard was to be added 
to a 384-microwell plate.  Because only 5 µL of dialysate sample was available for analysis, 20 
µL of phosphate buffered saline was added to the sample to make the total sample volume 25 µL.  
To that, 25 µL of 100X Thiol Green Indicator in Assay Buffer was added to each well.  Samples 
were allowed to incubate in the dark at room temperature for 50 minutes.  Samples were then 
analyzed using a SpectraMax Plus Microplate Reader at Ex: 490 nm, Em: 520 nm. 
 
4.2.2 abcam© GSH/GSSG Ratio Detection Kit Validation via LC-Fl 
In order to validate that the GSH assay kit would have linearity and limits of detection 
comparable to that of the more robust liquid chromatography-fluorescence system, samples were 
derivatized as describe above.  Derivatized samples were then analyzed on a liquid 
chromatographic system with fluorescence detection.  The system consisted of two Shimadzu LC-
10ADvp pumps, a 100 μL Shimadzu mixer, and a Rheodyne 9725i PEEK sample injector 
connected to a Phenomenex Synergi 4-μm Hydro-RP column (150 × 2.0 mm, Phenomenex, 
Torrance, CA) with a Phenomenex C18 guard cartridge. The binary gradient was controlled by a 
Shimadzu SCL-10vp system controller. Mobile phase A was 30 mM tetrabutylammonium 
hydroxide (TBA) in 25% methanol:75% water (v%:v%).  Mobile phase B was 30 mM TBA in 
100% methanol. The gradient was as follows: 0 - 2.0 min, 40% B; 2.0 - 3.5 min, 95% B; 3.5 – 4.0 
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min, 40% B; 4.0 – 6.0 min, 40% B.  The Shimadzu 10AXL fluorescence detector was operated at 
an excitation wavelength of 490 nm and an emission wavelength of 520 nm.  
 
4.2.3 TBARS Kit 
Samples were analyzed for MDA concentration using a commercially available 
Thiobarbituric Acid Reactive Substances (TBARS) Kit (Cayman Chemical, Ann Arbor, MI).  
Because the original kit instructions required a 100 µL sample volume, but only 4 µL were 
availabe, the kit had to be modified and optimized in order to obtain good linearity and required 
limits of detection.  The original kit assay required the following ratio of reagents: 100 µL 
sample/standard, 100 µL SDS, 4 mL of Color Reagent (50 mL of dilute acetic acid, 50 mL of dilute 
sodium hydroxide with 530 mg of thiobarbituric acid).  The final volume of 4 mL lead to too much 
dilution of the 4 µL sample and therefore did not produce a signal.  It was determined that three, 4 
µL samples would have to be combined to make a 12 µL sample volume.  The final reagent ratio 
was as follows: 12 µL sample/standard, 12 µL SDS, 200 µL Color Reagent.  Samples were mixed 
in locking microtubes (Fisher Scientific, Pittsburg, PA) and boiled for one hour.  After one hour, 
samples were placed in an ice bath for 10 minutes to stop the reaction.  200 µL of sample was 
placed in a 96-well black plate and analyzed using the SpectraMax Microplate Reader at Ex: 530 
nm and Em: 550 nm.   
 
4.2.4 TBARS Kit Validation via LC-Fl 
In order to validate that the MDA assay kit would have linearity and limits of detection 
comparable to that of the more robust liquid chromatography-fluorescence system, samples were 
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derivatized as describe above, following the kit instructions.  Derivatized samples were then 
analyzed on a liquid chromatographic system with fluorescence detection.  The same system, 
mobile phase, and gradient described above were used to test the MDA kit.  The Shimadzu 10AXL 
fluorescence detector was operated at an excitation wavelength of 530 nm and an emission 
wavelength of 550 nm.   
 
4.2.5 Surgical Procedures  
Animal experiments were carried out as described in Chapter 2.  Briefly, surgical tools were 
sterilized using ROCCAL® prior to every experiment.  Because these were not survival surgeries, 
autoclave sterilization was not necessary.  Male Wistar Rats weighing 300-450 grams were used 
in this study.   Rats were housed communally with free access to food and water until the time of 
the study.  Rats were placed in an isoflurane chamber and pre-anesthetized via isoflurane inhalation 
for 5 minutes.  The anesthetic cocktail of ketamine (80mg/kg)/ xylazine(10mg/kg) was 
administered I.P. and allowed to take effect.  Once the rat was fully anesthetized via the cocktail, 
the hair on the skull was shaved as closely as possible.  Booster doses of ketamine (40 mg/kg) 
were administered as needed to maintain adequate anesthesia. The animal's body temperature was 
maintained at approximately 37 °C using a PhysioSuite heating system. 
 
4.2.6 Microdialysis Brain Probe Implantation 
Once the rat was fully anesthetized, it was placed in the stereotaxic frame.   The rat was 
securely in place and an incision approximately 3 cm in length was made in the midline of the 
skull using a 10 blade scalpel.  Four tissue clamps were used to hold the skin to the side, and excess 
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tissue was removed using cotton tip applicators.  Once the skull was removed of excess tissue and 
blood, the bregma coordinates were determined.  The appropriate stereotaxic coordinates were 
calculated for the hippocampus (posterior 5.6 mm, lateral +4.8 mm, and ventral 5.0 mm).  Two 1 
mm holes were drilled arbitrarily around the desired probe location and anchor screws were 
inserted to serve as stability for the cannula.  Next, a 3 mm hole was drilled at the calculated probe 
site.  Once the hole had been drilled, the guide cannula was lowered to the appropriate depth and 
fixed to the skull with dental cement, covering the anchor screws.  After the dental cement 
solidified, the dummy probe was removed from the cannula and replaced with a CMA 12 
microdialysis probe with a 2 mm membrane length. The probe was perfused with either aCSF or 
3-MPA for the duration of the experiment.  The rat was maintained under anesthesia for the 
duration of the experiment using 40-50 mg/kg supplemental does of ketamine injected I.P. or I.M.  
At the termination of the experiment, the rat was euthanized using isoflurane overdose followed 
by decapitation.  The brain was harvested for histological analysis. 
 
4.2.7 Animal Experimental Design – Single Seizure  
Chapters 2 and 3 discuss the development of an animal model for locally induced epilepsy 
with the induction of two seizure episodes.  The animal experiments carried out in this study 
involved the induction of a single seizure.  This allowed us to investigate the oxidative damage, 







Post operatively, animals were allowed to recover for one hour during which time aCSF 
was constantly perfused through the microdialysis probe at a flow rate of 1.0 μL/min with a 
CMA/100 microinjection pump.  After a 60 minute recovery period, aCSF was perfused for one 
hour and collected in ten minute intervals to serves a basal level samples.  After the basal 
collection, a solution of 10 mM 3-MPA in aCSF was administered through the probe at a rate of 
1.0 μL/min for 30 minutes.  After the induction of the single, 30 minute seizure, aCSF was perfused 
through the probe for a total of 90 minutes.  These experiments serve as the controls for seizure 
induction.  For all experiments, samples were collected in ten minute intervals.  At the end of the 
experiment, the animal was euthanized via isoflurane overdose and decapitated for histological 
analysis.   
 
4.2.9 Sham 
To determine the raw amount of both GSH and MDA in the rat brain without any 
stimulation, sham experiments were performed.  The exact same experimental design and protocol 
was performed as described above; however, no epileptic agent was administered to the animal.  
Instead, a constant perfusion of aCSF was administered for the duration of the experiment.   
 
4.2.10 GSH Upregulation 
To increase the amount of GSH in the brain, the animal was dosed with ɣ-glutamylcysteine 
ethyl ester 24 hours prior to the surgery and seizure induction.  Animals were administered a 150 
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mg/kg dose of ɣ-glutamylcysteine ethyl ester.  The solid compound was dissolved in sterile saline.  
The animal was anesthetized briefly using an isoflurane chamber for easier handling and dosing 
and the ɣ-glutamylcysteine ethyl ester was administered in a single bolus IP injection.  The animal 
was marked and monitored until it was awake and freely moving.  Animals were allowed to have 
food and water ad libitum until they were ready for the probe implantation.    
 
4.2.11 GSH Downregulation  
To decrease the amount of GSH in the animal, a second, separate set of animals were dosed 
with buthionine sulfoximine (BSO) 24 hours prior to the surgery and seizure induction.   Animals 
were administered 160 mg/kg dose of BSO.  The solid compound was dissolved in sterile saline.  
Again, the animal was anesthetized briefly using an isoflurane chamber for easier handling and 
dosing and the BSO was administered in a single bolus I.P. injection.  The animal was marked and 
monitored until it was awake and freely moving.  Animals were allowed to have food and water 
ad libitum until they were ready for the probe implantation.    
 
4.3 Results and Discussion  
4.3.1 Derivatization Kits versus LC-Fl Validation  
Briefly, a GSH standard curve containing 8 concentrations was prepared ranging from 0.1563 
µM to 10 µM in aCSF every time the assay was performed.  Figure 4.4 shows a sample calibration 
curve obtained using the kit and microplate reader.  A correlation coefficient of 0.9957 was 
obtained with limits of detection of 10 nM (S/N=3). Figure 4.5 shows a calibration curve that was 
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generated following the kit protocol, but analyzed on the LC-FL system described above.  Figure 
4.6 is a representative chromatogram for a 10 µM sample.  Each concentration was run 4 times.  A 
correlation coefficient of 0.9986 with limits of detection of 8.7 nM (S/N=3).  While both the 
linearity and limits of detection appeard to be slightly improved using the LC-Fl system compared 
to the microplate reader, the LC-Fl analysis yielded less reproducible results, based on the variation 
of signal produced for each concentration, represented as the error bars.  The GSH samples are not 
very stable and need to be analyzed as quickly as possible, which is difficult with a 5 min analysis 
time.  This instability is what accounts for the large error bars on the LC-Fl calibration curve.  By 
using the microplate reader, the samples were analyzed all at once, and therefore in a fraction of 
the time,  reducing this deviation.  These tests were enough to support the use of the microplate 
reader over the LC-Fl system for the analysis of GSH in the dialysate samples.   
As stated earlier, for the TBARS kit detection of MDA, three, 4 µL samples had to be 
combined to make a 12 µL sample volume.  While this reduced our temporal resolution, it did 
provide enough sample to obtain a correlation coefficient of 0.9987 over the concentration range 
of 0.0625 to 5 µM with limits of detection of 50 nM (S/N=3).  An example calibration curve of 
this assay analyzed using the microplate reader is shown in Figure 4.7.   Once again, the kit was 
validated using the LC-FL system described above.  Figure 4.8 shows a calibration curve with N=4 
runs of each concentration on this system.  Figure 4.9 is a representative chromatogram for a 5 µM 
injection.  Linearity was an R2 =  0.9987 with limits of detection of 60 nM compared to the R2 =  
0.9986 with 50 nM limits of detection for the microplate analysis, showing little to no difference 
in the methods. Because the MDA-TBA adduct is much more stable than the GSH, reproducibility 









Figure 4.4: Relative Fluorescence Units versus Concentration calibration curve of GSH standards 
obtained from abcam© GSH/GSSG Ratio Detection Assay Kit analyzed on SpectraMax 



























Figure 4.5: Relative Fluorescence Units versus Concentration calibration curve of GSH standards 























Figure 4.6: Representative LC-FL chromatogram of 0 µM (Red) and 10 µM (Black) GSH-Thiol 
Green adduct. 
Tailing observed is most likely the cause of degradation products and excess Thiol Green 
Indicator.  
Reverse phase column; MP. A: 30 mM TBA in 25% MeOH:75% H2O (v%:v%),  MP. B: 30 




















analysis and results would be comparable.  We chose to use the microplate reader because the 
analysis time is a fraction of that of the LC-FL system.       
 
4.3.2 GSH Regulation   
GSH was quantified before, during, and after the seizure for all experimental conditions.  
Table 4.1 shows the GSH concentration numbers for each of these experimental manipulations.  
The relative concentration for basal extracellular concentration of GSH for all conditions was 
about 0.64 µM.  This is significantly less than the average expected basal concentration of 2 µM 
based on literature reports?6, 14.  It is possible that we are only getting about a 30% recovery of 
GSH in these in vivo experiments due to the extraction efficiency of the MD probe, and therefore 
the relative recovery should be measured to confirm this. One and two-tailed, independent sample 
t-tests were done to determine if there were significant changes between each group.  Table 4.2 
shows the statistical analysis of the data.  All conditions were statistically significant from each 
other with a confidence level of 90%.  It was found in the experiments that the basal levels of GSH 
for all conditions were essentially the same.  In the sham experiments, the concentration of GSH 
did not change significantly from basal.  This was to be expected because these animals did not 
receive any epileptic agent or GSH regulating compound.  However, there was a significant change 
in extracellular GSH concentration following a seizure induction.  There was an overall increase 
in extracellular GSH concentration during the seizure for all animals that experienced a seizure.    
The microdialysis samples from the BSO treated rats had lower concentration of GSH during 
the seizure compared to the control rats, approximately 39% less.  Furthermore, the ɣ-







Figure 4.7: Calibration curve of MDA standards obtained by Thiobarbituric Acid Reactive 



























Figure 4.8: Calibration curve of MDA standards obtained by Thiobarbituric Acid Reactive 



























Figure 4.9: Representative LC-FL chromatograms of 0 µM (Red) and 5 µM MDA-TBA adduct 
(Black).        
Tailing observed is most likely the cause of degradation products and excess TBA. 
Reverse phase column; MP. A: 30 mM TBA in 25% MeOH:75% H2O (v%:v%),  MP. B: 30 































Table 4.2: p-values from one and two-tailed, independent sample t-tests between GSH regulation 
experiments  
  
Sham Control Down Reg Up Reg
Basal 0.63 ± 0.01 µM 0.66 ± 0.02 µM 0.64 ± 0.01µM 0.52 ± 0.01 µM
Seizure 0.64 ± 0.01 µM 23 ± 8 µM 14 ± 4 µM 34 ± 8 µM
After 0.65 ± 0.01 µM 0.8 ± 0.3 µM 0.7 ± 0.1 µM 0.9 ± 0.4 µM








Down Reg 0.05 0.09




compared to the control rats.  This increase and decrease was as expected given the biochemical 
functions of BSO and ɣ-glutamylcysteine ethyl ester.  It was unexpected, however, that the basal 
levels of GSH did not change with GSH regulating compounds.  It was anticipated that the total 
GSH concentration would have changed, both extracellularly and intracellularly.    
While GSH is not typically thought of as a neurotransmitter, studies have shown that 
astrocytes and glial cells will release GSH and cysteine when under stress, deomonstrating that 
GSH functions not as a neurotransmitter, but as a release modulator of the redox cycle28, 29.  The 
GSH and cysteine are then available to be taken up by the neurons for synthesis of additional GSH 
to protect against oxidative damage29, 30.  This was observed in this research as well, and could 
explain why there was an increase in extracellular GSH during the seizure and subsequent return 
to basal after the seizure.  The astrocytes release GSH during the seizure, and then the neurons 
took up the GSH after the seizure.   
Alternatively, as discussed in Chapter 3, the induction of the seizure also results in significant 
membrane damage and cell death.  It is possible that the two GSH regulating compounds are 
affecting the intracellular GSH concentration only, and not the extracellular concentration.  
Therefore, when the seizure is induced, cells become damaged and spill their contents into the 
extracellular space.  Intracellular concentrations of GSH are on the millimolar range, 1000 times 
higher than the ECF.  This would account for such a high increase in extracellular GSH 
concentration during the seizure induction.  It is most likely a combination of astrocyte release and 
cell damage which leads to this GSH increase.   
In the future, GSSG should be monitored to see if the drop in GSH was accompanied with an 
increase in GSSG.  A shift in the GSH to GSSG ratio would help confirm induced oxidative stress, 
this is discussed later in this chapter.  Further experiments are necessary to make conclusions about 
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the large increase in GSH during the seizure induction.  However, the goal of the GSH regulating 
compounds was achieved.  BSO-dosed animals released less GSH compared to the respective 
controls and ɣ-glutamylcysteine ethyl ester dosed animals produced more GSH compared to the 
control experiments.  The purpose of this study was to investigate the effects of GSH concentration 
on oxidative stress in vivo due to seizure induction. 
 
4.3.3 MDA Production  
Based on previous research by Dr. Carl Cooley, an increase in MDA production with the 
induction of a local seizure was anticipated12.  Figures 4.10-4.12 are graphical representations of 
the changes in MDA concentration between the various experiments.  Initial evaluation of the data 
suggested an increase in MDA concentrations, however, after statistical analysis, these changes 
indicate that they are not significant.  One and two-tailed, independent sample t-tests were 
conducted comparing sham versus control, control versus GSH down regulated, and control versus 
GSH up regulated MDA values.  The p-values for each of these analyses are shown in Table 4.3.   
There was no significant difference in MDA production between any of the experiments, 
demonstrating that the results were too random to show any trend.  This was surprising considering 
the results of Dr. Cooley.  One possible explanation for this difference in results may have to do 
with the method of analysis.  Dr. Cooley analyzed his samples using a capillary electrophoresis-
fluorescence detection (CE-FL) system.  The use of CE allowed for smaller injection volumes and 
resulted in less dilution.  In his analysis, 5 µL of dialysate was derivatized and was 
hydrodynamically injected on the system.  The use of the TBARS kit required 12 µL of sample 








Figure 4.10: Comparison of sham versus control rats’ MDA production before, during, and after 
the seizure induction. 








Figure 4.11: Comparison of control versus GSH-upregulated rats’ MDA production before, 
during, and after seizure induction. 





























Figure 4.12: Comparison of control versus GSH-downregulated rats’ change in MDA production 
before, during, and after seizure induction. 































Table 4.3: p-values from one and two-tailed, independent sample t-tests for MDA production 
















Down Reg 0.17 0.34




It is possible that the sample preparation caused too much overall dilution, producing insignificant 
results.  Furthermore, because three samples had to be combined, there was a significant loss in 
temporal resolution.  It is possible that any significant changes in MDA are being missed due to 
the reduced time points. 
 
4.4 Future Directions 
4.4.1 Additional Malondialdehyde Studies  
Since no significant difference between the GSH enhanced and depleted rats for MDA, 
additional animals must be done in hopes that higher N values will lead to statistically relevant 
results.  Further modification and optimization of the TBARS assay should be made to reduce 
dilution and hopefully improve temporal resolution.  Implementing the CE-FL method developed 
by Cooley may be another option so that these studies can be directly compared to those that he 
performed.   
 
4.4.2 Role of Glutathione in Antioxidant Pathways 
As discussed briefly earlier, ROS can be neutralized by two mechanisms: enzymatic and 
nonenzymatic.  The three main enzymatic antioxidant pathways that involve GSH are glutathione 
peroxidase (GPx), glutathione reductase, and glutathione S-transferase (GST)5.  GPx catalyzes the 
reduction of hydrogen peroxide in the presence of GSH to produce water and GSSG15.  An increase 
in GSSG production could signify an increase in hydrogen peroxide, and therefore oxidative stress.  
Additionally, glutathione reductase catalyzes the reduction of GSSG using NADPH to produce 
two GSH molecules, which occurs when there is an imbalance in ROS in the body16.  This process 
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occurs when there is an imbalance in ROS in the body.  To improve on the research conducted in 
this chapter, it would be beneficial to also measure GSSG concentration.  Oxidative damage can 
be quantified by measuring the ratio of GSH to GSSG.  Measuring both GSH and GSSG would 
not only provide this ratio, but depending on the ratio shift could provide information on if GPx 
versus glutathione reductase was being affected in the experiments.   
Finally, GST can conjugate GSH with electrophilic organic compounds.  An activation of 
GST can reduce GSH levels, which can be detrimental to the body31.  One specific study by 
Nagashima et al. suggests that GST activity was reduced after seizures to increase the amount of 
GSH available for ROS scavenging32.  Furthermore, GST is also believed to help reduce lipid 
peroxidation by combining GSH with hydrophobic compounds to make them more water-soluble 
so they can be removed from the system33.  Modifying GST activity may be more successful in 
modulating MDA production.   
It would be beneficial to test different upregulating and downregulating compounds to see if 
they resulted in different effects.  Specifically, diethyl maleate works to decrease GSH by forming 
an adduct with reduced GSH, which then gets metabolized by glutathione-S-transferase34.  Diethyl 
maleate is faster-acting than BSO, but it is short-lived.  This different mechanism should be 
explored to see if it produces different results.  
 
4.5 Conclusions  
The research discussed in this chapter was an investigation of the correlation between local 
seizures and oxidative damage.  Chapter 3 demonstrated that significant cell damage was occurring 
during the seizure induction.  It was anticipated that this damage was related to lipid peroxidation.  
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MDA was the biomarker selected to quantify the amount of lipid peroxidation because it is a very 
stable byproduct of these reactions.  Unfortunately, there was no statistically significant change in 
MDA production between the various experiments.  GSH was selected as a natural antioxidant 
that could be easily regulated in vivo.  GSH was successfully upregulated and downregulated in 
vivo, however it still remains unclear which specific enzymatic pathways are being affected.    
Additional experiments must be done before further conclusions can be made.  Specifically, 
measuring GSSG concentration, as well as glutathione peroxidase, reductase and GST activity 
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Chapter 5  
Summary and Future Directions 
5.1 Summary of the Research  
The research discussed in this dissertation was a study of the correlation between locally 
induced seizures and oxidative damage.  Chapter 2 discussed the development of an animal model 
for locally induced epilepsy.  By definition, patients are diagnosed with epilepsy after experiencing 
two or more seizures.  The goal of this work was to induce two local seizures within one animal 
experiment, thereby developing a model for locally induced epilepsy.  Various intra-seizure time 
delays were explored.  It was determined that 150 minutes were required for basal levels of 
neurotransmitters to be reestablished after the induction of the first seizure.  The return to basal 
levels prior to the second seizure induction signifies two separate seizure events.   
Unexpectedly, there was significant attenuation in glutamate release observed in the second 
seizure stimulation.  Chapter 3 discussed a series of experiments that were performed to test 
various biochemical and neurochemical pathways which could be responsible for the observed 
glutamate diminution.  It was determined that a combination of mitochondrial starvation and cell 
death lead to the glutamate depletion.  Lactate supplementation of the perfusate helped encourage 
the KREB cycle production of glutamate, resulting in a significant increase in glutamate release in 
the second seizure episode.   This verifies that the cells were being starved for key precursors to 
glutamate biosynthesis.  Additionally, it was determined that 30-38% of the cells died prior to the 
induction of the second seizure episode.  Because of this cell death, the neurons were unable to 
release additional glutamate.  Further development and investigation of this model is necessary for 
it to be a working model for locally induced epilepsy.  Lower concentrations of 3-MPA or different 
epileptic agents should be investigated to reduce the amount of damage being caused.     
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Chapter 4 discussed an investigation of epilepsy-induced oxidative damage and an attempt to 
mitigate lipid peroxidation by modulating the amount of the natural antioxidant GSH in the body.  
A series of experiments were carried out including, sham dosing, control, GSH upregulation, and 
GSH downregulation.  Unfortunately, there was not a significant change in MDA production for 
any of the experiments; however, the overall goal of regulating GSH was achieved. It was 
concluded that the addition of up- and down-regulating compounds were able to modulate the 
amount of intracellular GSH, but not necessarily the amount of extracellular GSH.  Increases in 
extracellular GSH were observed in all animals that experienced a seizure.  Furthermore, GSH 
levels almost returned to basal after the seizure which could signify that the GSH was being 
released from astrocytes to combat the oxidative stress being cause by the seizure.  In the future, 
GSSG should be monitored to see if the drop in GSH was accompanied with an increase in GSSG.  
Likewise, monitoring glutathione enzymatic pathways could provide additional insight on the 
involvement of GSH as an antioxidant.   
 
5.2 Future Directions  
5.2.1 MDA Measurement in Multiple Seizure Model  
To further develop the project discussed in Chapter 4, MDA will be measured in the multiple 
seizure model.   Significant cell damage is being observed in the two seizure model.  It is 
anticipated that there would be compounding lipid peroxidation with additional seizures.  
Preliminary experiments have been done measuring MDA in the supplemented two seizure animal 
experiments.  Figure 5.1 shows this preliminary data.  There was an increase in the amount of 
MDA in the second seizure in both the glucose and lactate supplemented experiments.  This is to 
be expected.  Glucose and lactate caused an increase in glutamate release in the second seizure 
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induction.  This increase in glutamate release could lead to increased excitotoxicity, causing more 
oxidative damage.  Interestingly, with the DHK experiments, there was a slight decrease in the 
amount of MDA produced.  As discussed in Chapter 3, there was no apparent difference in the 
amount of glutamate release in the control experiments compared to the DHK supplemented 
experiments.  The N-values are not high enough to determine if these differences are statistically 
significant or not, and therefore additional animal experiments need to be done.  Unfortunately, no 
multiple dose control experiments nor sham experiments were analyzed for MDA.   It would be 
interesting to analyze both the control and sham experiments for MDA concentration to determine 
basal levels of MDA from the probe implantation itself as well as multiple seizure induction 
without supplements.  However, this data does show potential of compounding oxidative damage 
with subsequent seizures.   
 
5.2.2 Additional Lipid Peroxidation Pathways 
To further confirm the relationship between oxidative damage and locally induced epilepsy, 
additional biomarkers should be investigated.  Our lab has worked to develop analytical methods 
for several of these biomarkers including 8-OHdG, 8-oxoG, prostaglandins, Coenzyme Q10 
(CoQ10), and Phospholipase A2, all of which can be easily monitored.  This section discuses several 
experiments to modulate lipid peroxidation.   
When DNA gets damaged by oxidation, the guanine bases lead to the production of 8-
hydroxyguanine lesions that result in G-T conversions, further destroying the DNA.  One way to 
help repair these lesions is through base excision repair1-3.  This repair leads to the end products 












Figure 5.1: Preliminary results of MDA measured in multiple seizures. 
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induced DNA damage.  A capillary electrophoresis-electrochemical detection method has been 
developed in our lab that can be used to detect these compounds4.      
Another biomarker for the inflammatory response to oxidative stress are prostaglandins (PGs).  
They can be used as a biomarker for the enzymatic breakdown of arachidonic acid (ARA).  The 
most common PGs formed during an inflammatory response are PGE2, PGD2, and PGF2
5-7.  We 
are interested in modulating cyclooxygenase (COX) pathways to affect the production of ROS as 
well as the breakdown of ARA.  COX-1 and COX-2 are enzymes that are involved in the formation 
of oxygen free radicals8.  They are also involved in the conversion of ARA into prostaglandins.  
The COX pathways naturally become accelerated during seizure induction, which can be seen by 
an increase in ROS, leading to lipid peroxidation and therefore prostaglandin production.  In hopes 
to reduce this damage, a COX inhibitor such as indomethacin could be administered to the animals 
prior to the induction of the seizures. Indomethacin would block the activation of the COX 
pathway, hopefully reducing the amount of lipid peroxidation and DNA damage.   Literature has 
shown that dosing indomethacin to seizure-susceptible rodents has decreased both the DNA 
damage associated with the seizure as well as the frequency of seizures9.  By giving the rat 
indomethacin prior to the induction of the seizures, we anticipate to see a decrease in lipid 
peroxidation biomarkers such as prostaglandins and MDA.    
As discussed in Chapter 3, it is apparent that using 3-MPA to induce seizures leads to 
mitochondrial starvation.  To further investigate this hypothesis, coenzyme Q10 (CoQ10) can be 
modulated to hopefully decrease the amount of mitochondrial dysfunction.   Studies have shown 
that CoQ10 can work as a preventative drug for neurodegenerative diseases and mitochondrial 
myopathies10-12. CoQ10 functions to move electrons between the redox components of the electron 
transport chain within the mitochondrial membrane, increasing the generation of ATP.  During 
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oxidative stress, there is a breakdown of electron transport across the mitochondrial membrane, 
leading to an increase in free radicals and ROS.  By dosing animals with CoQ10 for an extended 
period of time prior to seizure induction, the relationship between CoQ10 and seizure induced 
oxidative damage could be explored.    
Finally, to further investigate seizure induced lipid peroxidation, phospholipase A2 (PLA2) 
could be modulated.  PLA2 is the enzyme responsible for the release of ARA from cell membranes.  
The influx of Ca2+ ions during a seizure activate the calcium-dependent PLA2 or cPLA2
13, 14.  This 
activation leads to an increase in ARA and therefore lipid peroxidation.  Palmitoyl trifluoromethyl 
ketone (PACOCF3) is a non-specific inhibitor of both calcium dependent and independent PLA2.  
Giving PACOCF3 to the rats prior to the induction of the seizure will decrease the amount of lipid 
peroxidation by preventing ARA release from cell membranes.  It is evident that oxidative stress 
affects a multitude of complex pathways, all of which can play a key role in understanding locally 
induced epilepsy.          
 
 
5.2.3 Other Models for Epilepsy  
5.2.3.1 Awake Studies  
All of the animal models discussed in this dissertation were anesthetized.  While this allows 
for a more controlled system, the anesthetic effects can significantly alter neurochemical 
responses.  Ketamine specifically has been shown to lead to spikes and dips in dopamine and 
serotonin15, 16.  By allowing the animal to wake up after the microdialysis probe implantation, the 
animal will have sufficient time to recover from the surgery, reducing any inflammation and 
excitation caused by the surgery.  This would allow the experiment to extend from hours to days 
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and possibly even weeks.  This allows for the potential to add additional seizures to the animal 
model.  Significant glutamate diminution was observed in the second seizure episode.  Another 
way to further investigate the glutamate attenuation would be to add additional seizures to the 
model; third and fourth seizure responses could then be compared.  Allowing the animal to be 
awake for the duration of the experiment would also permit increased time between seizure 
inductions.  Currently, the model requires 150 minutes of recovery after the first seizure before 
basal levels are established; however, it is evident that this is still not enough time for the entire 
biochemical system to be restored based on the results in Chapter 3.  In an awake study, 
intraseizure time could be increased to days rather than hours.    
 
5.2.3.2 Kindling Model   
Finally, as discussed briefly in Chapter 1, kindling models for epilepsy are most 
representative of clinical human patients.  In these models, a subconvulsant dose of an epileptic 
agent is given to an animal everyday over time until the animal becomes sensitized to the epileptic 
agent and begins experiencing seizures.  The seizures are unpredictable, similar to seizures in 
human patients.  Rocha et al. has previously developed a kindling model for epilepsy using 
pentylenetetrazol (PTZ), which could be adapted for comparison to our 3-MPA model.  Awake 
animal experiments could also be implemented in this study17, 18.  A microdialysis probe would be 
implanted into the hippocampus of the rat.  The animal would then be able to wake up and recover 
from surgery.  The animal would be administered PTZ every day until the animal experiences 
consecutive seizures, signifying that the kindling has taken effect19, 20.   
Similar to the anesthetized, induced model, samples would be collected before, during, and 
after the compound administration.  It is hypothesized that subsequent doses of PTZ will lead to 
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an increase in seizure activity and the production of ROS and RNS, thereby resulting in oxidative 
damage.     
 
5.3 Final Conclusions  
All of the data presented here demonstrates the complexity of the biochemical processes that 
occur as a result of seizure induced oxidative stress.  While significant progress in understanding 
the correlation between local seizures and oxidative damage, specifically lipid peroxidation, has 
been made with this research, there will always be more questions to be answered and more 
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Investigation of Human Plasma Protein Binding by Microdialysis Sampling   
Background and Significance 
Measurement of plasma protein binding (PPB) of drugs is critical to understanding their 
pharmacokinetics and efficacy.  According to the free drug hypothesis, only the fraction of the 
drug that remains unbound to serum proteins is responsible for its therapeutic activity1.  One 
method that can be employed to measure the free drug fraction is microdialysis sampling.  This 
technique can be applied both in vitro and in vivo, making it an attractive technique in preclinical 
drug discovery2.  In this study, plasma protein binding of five commercially available, albumin 
binding compounds with known PPB values was measured using microdialysis sampling.  
Perfusate modifications were investigated to achieve optimal compound recovery while reducing 
nonspecific binding to the membrane.  It was determined that plasma ultrafiltrate served as the 
best perfusate option, as it did not negatively impact the extraction efficiency of the probe or 
compound PPB.  In addition, plasma ultrafiltrate mimics in vivo physiological matrices, allowing 
for easy transition to in vivo microdialysis studies. 
 
Plasma Protein Binding  
When a drug is introduced to a biological system, a portion of the drug becomes unavailable 
to elicit a pharmacological effect due to binding to proteins such as human serum albumin or 
globulins (e.g. alpha-1-acid glycoprotein).   Only the free drug fraction is accessible to drug 
transporters and drug metabolizing enzymes, as well as the intended drug target3-5.   The extent of 
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PPB influences the distribution of the drug in the body and is therefore routinely measured during 
optimization of potential candidates during drug discovery.  The ability to accurately measure the 
unbound fraction (fu) of a drug is critical to understanding both the pharmacokinetics and 
pharmacodynamics of the drug6.  Multiple techniques are available for measuring fu of drugs in 
vitro including equilibrium dialysis (ED) and ultrafiltration (UF) and have been reviewed 
extensively elsewhere7-10.  Currently, classical equilibrium dialysis is considered the gold standard 
for definitive measurement of plasma protein binding11.  Rapid equilibrium dialysis (RED) has 
improved PPB throughput of binding studies, making it a highly utilized screening technique12.  
While the RED device allows for parallel processing of multiple samples at the same time, the 
assay still requires long incubation times for equilibrium to be established, making the technique 
time consuming12.  UF is a quicker technique, reducing equilibrium time from hours to minutes. 
However, this method is highly susceptible to nonspecific binding of the compound to the device 
and typically has a very low throughput, making the assay time consuming resulting in loss of 
sample13.  More recently, microdialysis (MD) has emerged as an alternative to ED and UF for 
measuring PPB in vitro2, 14-18. 
 
Human Serum Albumin 
Human serum albumin (HSA) is the most abundant protein in human blood, making up nearly 
50% of all serum proteins19.  It is produced in the liver and its primary function is to maintain the 
oncotic pressure in the body which is needed for the distribution of bodily fluids between the blood 
vessels and tissue6.  It can also function to transport hormones, fatty acids, and other small 
compounds, such as drugs, through the body.  Small compounds are able to bind to HSA, allowing 
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them to be transported to the liver.  This binding also affects the drug’s half-life and metabolism.  
All of the drugs investigated in this study were HSA binding compounds.   
 
Free Fraction 
It is widely accepted that it is the free fraction of drug that is pharmacologically active.  This 
is the fraction that interacts with receptors, is metabolized, and ultimately excreted.  This concept 
is known as the free drug hypothesis.  Most drug targets are in the tissues themselves and not in 
the vasculature.  This makes measuring the free fraction very difficult in the pre-clinical and 
clinical setting.  By measuring the free fraction in the vasculature, i.e. blood plasma, 
pharmaceutical researchers can get an idea of the amount of free drug in the body, assuming the 
amount of drug in the plasma is in equilibrium with the amount at the active site1.   Accurately 
measuring the amount of free drug in the body is essential for drug development and determining 
the optimal dosage.  Because only the free fraction is available to generate a pharmaceutical effect, 
the amount of protein binding is directly proportional to dosage4.  Several techniques are available 
to measure the PPB values, all with advantages and disadvantages and are described in detail 
below.  
 
Common Methods of Measurement 
Ultrafiltration 
Ultrafiltration is an in vivo microsampling technique in which sampling occurs across a 
semipermeable membrane.  For ultrafiltration sampling, a vacuum is applied to the probe and 
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sampling occurs via bulk transport of ECF into the probe instead of diffusion driven with 
microdialysis sampling.  Since bulk ECF is collected, the analyte concentration in the sample is 
the same as that in the tissue and calibration is not required.  The most common sampling sites for 
ultrafiltration are subcutaneous tissue and biological fluids, such as blood10, 13.  Denser tissues, 
such as in the brain, are unsuitable for ultrafiltration sampling, limiting its versatility.  Furthermore, 
due to the high vacuum required the plasma protein binding values can be altered by potential 
changes in protein concentration due to the abrasive pressure of the sampling. 
 
Equilibrium Dialysis 
Similar to classical dialysis, equilibrium dialysis (ED) involves the passing of molecules 
across a semipermeable membrane.  ED is a specific application of dialysis that involves the 
binding of small molecules to proteins.  Small molecules such as drugs, are allowed to passively 
diffuse across a membrane from one chamber to another across a semipermeable membrane with 
a low molecular weight cut-off1, 11.  This is allowed to happen for a length of time (typically 18 
hours) until equilibrium is established.  The set-up is relatively simple and easy to implement, 
making it an attractive option.  However, the length of time for equilibrium to be established is 
quite lengthy, reducing data output.  
 
Rapid Equilibrium Dialysis  
Finally, rapid equilibrium dialysis (RED) can also be used to measure concentrations in the 
extracellular fluid in vitro; however, the device cannot be implanted directly into an animal, 
therefore, it is not applicable to in vivo studies.  With major applications for ADME and 
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pharmacokinetic studies, rapid equilibrium dialysis is an improvement on traditional equilibrium 
dialysis.  The RED apparatus consists of Teflon based plates containing disposable dialysis cells, 
shown in Figure 1.112.  They are comprised of single-use disposable two-sided chambers that can 
be filled with sample and sample matrix.  Over time, the free drug is allowed to passively diffuse 
across the membrane and is then collected in one of the two chambers.  The inserts can be placed 
in a 96-well plate which makes it easy for high through-put analysis.  While this is an excellent 
way to perform plasma protein binding studies, there are still limitations to this technique.   The 
quickest time achievable for the study is 100 minutes.  Because there is no laminar flow involved, 
it takes a long time for complete diffusion to occur and for equilibrium to be established.  For this 
reason, implementing microdialysis to perform PPB studies can be a faster, just as reliable method 
for studying drug binding both in vitro and in vivo.   
 
Microdialysis in PPB Studies 
In MD sampling, a probe containing a semi-permeable membrane with a low molecular 
weight cut-off (e.g. 20 kDa) is placed into the sampling space such as the brain, liver, or vein.  
Matrix-compatible solution, termed perfusate, is slowly pumped through the probe allowing small 
analytes to cross the membrane by passive diffusion that is driven by a concentration gradient, 
allowing for both recovery of free compound in the sample and delivery of compounds to the 
surrounding matrix20-22.  Small molecules diffuse across the membrane depending on the direction 
of the concentration gradient and are collected as dialysate.  The low molecular weight cutoff of 
the membrane prevents large macromolecules, such as proteins and blood cells, from crossing into 

















fraction of the drug is collected, making this technique ideal for PPB studies using direct 
sampling15, 22. 
Previous studies have demonstrated the utility of microdialysis to measure plasma protein 
binding in vitro15, 21.  In these studies, low and moderately bound drugs, (i.e., fu = 90-50%) were 
investigated using long membrane lengths, (up to 30 mm) to increase analyte recovery.  While 
these studies demonstrated the basic application of MD to in vitro PPB studies, difficult to monitor 
compounds including those that are extensively protein bound (>95%) or subject to significant 
non-specific binding to PPB device components, were not taken into consideration.  While the 
long membrane length improved overall analyte recovery, it is not practical for use in in vivo 
applications due to the loss of spatial resolution.  Therefore, the goal in the present studies was to 
use optimized microdialysis sampling techniques to accurately measure the protein binding of 
difficult compounds including warfarin and rosiglitazone in vivo.   
The current study has improved on previous work by expanding the range of protein bound 
compounds to include extensively bound compounds.  Additionally, the probe membrane length 
has been significantly reduced to 10 mm, making it more applicable to in vivo studies.  Five 
commercially available albumin binding drugs (Table 1.1) with reported UF or ED PPB values 
including extensively protein bound drugs and those subject to significant nonspecific binding, 
were successfully monitored with the addition of perfusate modifiers, further demonstrating the 










Compound % Bound Literature5, 23-25 Literature Method 
of Measurement 
Levofloxacin 25-38% RED12 
Carbamazepine 63.7-82.5% UF26 
Warfarin 96-99% UF13/RED11, 12 
Clozapine 84-95% RED12 
Rosiglitazone 99.8% UF23 
 




Probe Considerations  
Several factors play a role in selecting the appropriate MD probe for the study.  Sampling 
location is the initial parameter.  For plasma studies, a flexible probe is most ideal because it can 
not only be used in vitro but can then be easily implanted in the vasculature for in vivo studies.   
Other factors such as membrane length, membrane type, and molecular weight cut-off are 
important considerations to make27.  All parameters greatly affect analyte delivery and recovery.  
Longer membrane lengths, for example, provide more surface area of analytes to defuse across; 
however, spatial resolution is greatly compromised.  There are a variety of membrane materials 
available including polycarbonate (PC), polyarylethersulphone (PAES), cuprophan, and cellulose 
acetate.   Membrane material selection is directly related to the hydrophobicity and hydrophilicity 
of your analyte.  Hydrophobic analytes will prefer a hydrophobic membrane and vice versa.   
 
Materials and Methods 
Chemicals 
All compounds were purchased from Sigma Aldrich (St. Louis, MO).  Ringer’s Solution was 
purchased from VWR (Philadelphia, PA).  Pooled, mixed gender, heparinized human plasma and 
plasma ultrafiltrate were purchased from BioreclamationIVT (New York, NY). The plasma 
ultrafiltrate was pooled, mixed gender, heparinized human plasma filtered using ultra-filtration 






CMA 20 Elite Microdialysis Probes were purchased from Harvard Apparatus (Holliston, MA, 
USA).  Probes consisted of a 10 mm polyarylethersulphone (PAES) membrane with a 20 kDa 
molecular weight cutoff.  Probes were flexible and had 200 mm of tubing on either side of the 
membrane.  The probes and tubing were filled with perfusion fluid and checked for proper flow 
prior to sample collection. 
 
In Vitro Microdialysis 
Extraction Efficiency 
In order to accurately quantify the amount of free drug in the matrix of interest, the extraction 
efficiency for a given probe was determined.  Extraction efficiency studies were carried out in 
vitro in 4 mL amber glass vials at 37°C and stirred constantly at 350 rpm with micro stir bars 
(Figure 1.2).  3 mL of Ringer’s solution (99.28% water, 0.68% sodium chloride, 0.02% sodium 
bicarbonate, 0.01% potassium chloride, 0.01% calcium chloride dehydrate) was spiked with 1 µM 
of compound.  The probe was placed in the vial, ensuring that the entire membrane was submerged 
in the solution.  Analyte-free Ringer’s solution was pumped through the probe at a flow rate of 1 
µL/minute using a syringe pump.  Samples were collected in 20 minute intervals.   
 
Probe Validation 
To verify probe integrity for the duration of the experiment, nadolol samples were collected 
before and after the experiment to serve as controls.  Nadalol was chosen as the control because it 
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has similar chemical properties as the compounds of interest, but was not highly susceptible to 
non-specific binding.  The probe integrity was validated if nadalol extraction efficiencies from 
before and after the experiment matched within a 20% threshold.  The extraction efficiency of the 
probe was determined for each compound by collecting triplicate dialysate samples along with 20 
µL aliquots from the sample vial to determine the actual spiked concentration.  The analyte 
concentration in the collected dialysate was then determined analytically using liquid 
chromatography-tandem mass spectrometry (LC-MS) and probe recovery was calculated using 
equation 1 were Cdialysate is the concentration of compound measured in the dialysate and Csample is 
the concentration of compound spiked into the vial.  Extraction efficiency measurements were 





Plasma Protein Binding of Commercial Compounds 
Once the extraction efficiency of each compound had been determined, protein binding 
studies were carried out in the same manner as the extraction efficacy, replacing the Ringer’s 
solution in the vial with 3 mL of pooled, mixed gender, heparinized human plasma and spiking it 
with 1 µM of test compound.   Once again, three, 20 minute samples were collected.  This was 
repeated three times for a total of nine collections.  A blank plasma dialysate sample was collected 
between each triplicate set.  Samples were diluted to 2 or 3 fold depending on the analyte and 




 x 100 
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2, where Cdialysate is the experimentally determined free drug concentration, percent probe recovery 
is the calculated extraction efficiency, and CRT is the concentration of analyte spiked into the 






Liquid Chromatography – Mass Spectrometry  
Method Optimization 
A generic LC-MS method was modified and optimized for sample analysis28, 29.  Dialysate 
samples were collected directly into a 96 well plate and diluted by adding 50:50 (v/v) 
acetonitrile/Ringer’s solution to the samples to be within the linear range of the calibration curve.  
A sample calibration curve for clozapine is shown in Figure 1.3.  Standards were made in their 
respective perfusate used in each of the protein binding studies.  Concentrations tested ranged from 
0.5 nM to 1000 nM and demonstrated linearity with R2= 0.9998 and a lower limit of quantitation 
of 0.1 nM, with a S/N=10.  1000 ng/mL tolbutamide was added to all samples and standards to 
serve as an internal standard.  The plate was vortexed, centrifuged, and placed on the auto sampler 
for injection.  All compounds were detected in positive ionization mode.  Each drug was 
individually infused to determined optimal parameters.  Samples were analyzed using a SIL-HTc 
autosampler/system controller with two LC-20AD Shimazdu pumps and an Applied Biosystems  

























Figure 1.2: in vitro microdialysis set-up 
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AB MDS Sciex 4000 Q Trap mass spectrometer operated in MRM mode.  The analysis time was 
5 minutes with a linear gradient of solvent A: water with 0.1% formic acid and solvent B: 
acetonitrile with 0.1% formic acid at a flow rate of 0.500 mL/min.    
 
Quality Control  
In order to validate the concentrations of the standard and therefore the standard curve, 
quality control samples were also run in parallel with the standard and samples.  Quality control 
samples were run in triplicate with a low, mid, and high concentration within the calibration curve.  
Quality control samples needed to be within 25% of the curve standards to be considered passing, 
thereby validating the standards to be used for quantitation.     
 
Perfusate Modifications 
Protein binding experiments with perfusate modifiers were carried out as described above.  In 
the modified experiments, the Ringer’s solution in the perfusion needle was replaced with either 
5% human serum albumin (HSA) in Ringer’s, or with plasma ultrafiltrate.  Similarly, standards 
were made up in the respective modified solutions for LC-MS analysis.   
 
Results and Discussion  
Extraction efficiencies and protein binding were experimentally determined for 5 
commercially available albumin binding compounds ranging in protein binding from 12% bound 









Figure 1.3: Representative calibration curve of clozapine in Ringer’s solution.   



























currently available methods (Table 1.2).  A variety of compounds were investigated to increase 
extraction efficiency and obviate non-specific adsorption.    
 
Human Serum Albumin 
In an attempt to increase the extraction efficiency of the probe for the measurement of 
extensively protein bound drugs, 5% HSA was added to the Ringer’s solution perfusate to increase 
the drug’s affinity for the perfusate, and to decrease nonspecific binding to the microdialysis 
components.  Recoveries of over 100% were obtained for highly and extensively bound drugs.  
One hypothesis for these high recoveries is the free drug is binding to the HSA and then being 
released upon the denaturing of the protein in the dialysate prior to analysis.  Recoveries for low 
and moderately bound drugs were significantly lower in HSA modified perfusate in comparison 
to unmodified Ringer’s.  This is most likely due to the compound affinity and binding properties 
to HSA versus other plasma proteins, since no HSA was added to the sample vial.  While the 
extraction efficiencies were significantly affected by the addition of HSA to the perfusate, it should 
be noted that the protein binding numbers were not affected do to the mathematical calculation.  
PPB values determined using HSA modified perfusate matched reported ED/UF literature values 
reasonably well.   
 
Plasma Ultrafiltrate  
To remove the need to denature the proteins associated with the HSA modification, plasma 
ultrafiltrate was additionally tested as a perfusion fluid.  Ultrafiltrate was selected in an attempt to 
closely mimic the sampling medium, plasma, but remain protein free (> 10Kda) for easier sample 
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cleanup and analysis.  Table 1.2 shows that the ultrafiltrate did not significantly affect the 
extraction efficiency of the probe and also allowed for extensively bound drugs to be measured.  
Because the plasma ultrafiltrate is protein-free, there were no sites available for drug to bind to the 
perfusate, thereby removing the issue of extraction efficiencies over 100%.  Protein binding 
numbers measured using ultrafiltrate as the perfusion fluid match literature values for compounds 
from all levels of protein binding, further validating it as an ideal perfusate option.  Additionally, 
plasma ultrafiltrate directly mimics the physiological matrix, making for an easy transition to in 
vivo experiments. Future exploration of this project would include investigation of different 
perfusate modifications or additivities to further increase compound recovery.  Once the in vitro 
PPB parameters have been fully optimized, they can be directly applied to in vivo pharmacokinetic 
and pharmacodynamic studies.   
 
Conclusions and Future Directions 
From this limited compound set, it can be concluded that plasma ultrafiltrate may be used as a 
universal perfusion fluid for the accurate measuring of low to extensively protein bound 
compounds using microdialysis.  Additionally, because plasma ultrafiltrate is a direct match of 
physiological conditions, the transition to in vivo studies could easily be carried out without further 
methodological modifications.  MD allows for real time monitoring of PPB measurements, making 












































































































































































































































































1. Di, L., Umland, J. P., Trapa, P. E., and Maurer, T. S. (2012) Impact of recovery on fraction 
unbound using equilibrium dialysis, Journal of Pharmaceutical Sciences 101, 1327-1335. 
2. (2011) Applications of Microdialysis in Pharmaceutical Science, Wiley, Hoboken, US. 
3. Bohnert, T., and Gan, L.-S. (2013) Plasma protein binding: From discovery to 
development, Journal of Pharmaceutical Sciences 102, 2953-2994. 
4. Dasgupta, A. (2007) Usefulness of monitoring free (unbound) concentrations of 
therapeutic drugs in patient management, Clinica Chimica Acta 377, 1-13. 
5. Jensen, B., Chin, P., and Begg, E. (2011) Quantification of total and free concentrations of 
R- and S-warfarin in human plasma by ultrafiltration and LC-MS/MS, Anal Bioanal Chem 
401, 2187-2193. 
6. Schmidt, S., Gonzalez, D., and Derendorf, H. (2010) Significance of Protein Binding in 
Pharmacokinetics and Pharmacodynamics, Journal of Pharmaceutical Sciences 99, 1107-
1122. 
7. Brocks, D. R. (2006) Drug disposition in three dimensions: an update on stereoselectivity 
in pharmacokinetics, Biopharmaceutics & Drug Disposition 27, 387-406. 
8. Ruiz-Garcia, A., Bermejo, M., Moss, A., and Casabo, V. G. (2008) Pharmacokinetics in 
Drug Discovery, Journal of Pharmaceutical Sciences 97, 654-690. 
9. Wang, H., Zrada, M., Anderson, K., Katwaru, R., Harradine, P., Choi, B., Tong, V., 
Pajkovic, N., Mazenko, R., Cox, K., and Cohen, L. H. (2014) Understanding and Reducing 
the Experimental Variability of In Vitro Plasma Protein Binding Measurements, Journal 
of Pharmaceutical Sciences 103, 3302-3309. 
179 
 
10. Lam, H., Davies, M., and E. Lunte, C. (1996) Vacuum ultrafiltration sampling for 
determination of plasma protein binding of drugs, Journal of pharmaceutical and 
biomedical analysis 14, 1753-1757. 
11. van Liempd, S., Morrison, D., Sysmans, L., Nelis, P., and Mortishire-Smith, R. (2011) 
Development and Validation of a Higher-Throughput Equilibrium Dialysis Assay for 
Plasma Protein Binding, Journal of the Association for Laboratory Automation 16, 56-67. 
12. Waters, N. J., Jones, R., Williams, G., and Sohal, B. (2008) Validation of a rapid 
equilibrium dialysis approach for the measurement of plasma protein binding, Journal of 
Pharmaceutical Sciences 97, 4586-4595. 
13. Wang, C., and Williams, N. S. (2013) A mass balance approach for calculation of recovery 
and binding enables the use of ultrafiltration as a rapid method for measurement of plasma 
protein binding for even highly lipophilic compounds, Journal of pharmaceutical and 
biomedical analysis 75, 112-117. 
14. Brunner, M. Microdialysis: an in vivo approach for measuring drug delivery in oncology, 
European journal of clinical pharmacology 58, 227-234. 
15. Hansen, D. K., Davies, M. I., Lunte, S. M., and Lunte, C. E. (1999) Pharmacokinetic and 
Metabolism Studies Using Microdialysis Sampling, Journal of Pharmaceutical Sciences 
88, 14-27. 
16. J. (2011) Clinical microdialysis in neuro-oncology： principles and applications - Clinical 
microdialysis in neuro-oncology： principles and applications, Ai zheng 30, 173-181. 
17. Mathy, F.-x., Preat, V., and Verbeeck, R. K. (2001) Validation of subcutaneous 
microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat, Journal of 
Pharmaceutical Sciences 90, 1897-1906. 
180 
 
18. Verbeeck, R. K. (2000) Blood microdialysis in pharmacokinetic and drug metabolism 
studies, Advanced Drug Delivery Reviews 45, 217-228. 
19. Zhivkova, Z., and Doytchinova, I. (2012) Quantitative structure—plasma protein binding 
relationships of acidic drugs, Journal of Pharmaceutical Sciences 101, 4627-4641. 
20. Joukhadar, C. (2005) Microdialysis - Current applications in clinical pharmacokinetic 
studies and its potential role in the future, Clinical pharmacokinetics 44, 895-913. 
21. Mukker, J. K., Singh, R. P., and Derendorf, H. (2014) Determination of Atypical Nonlinear 
Plasma–Protein-Binding Behavior of Tigecycline Using an In Vitro Microdialysis 
Technique, Journal of Pharmaceutical Sciences 103, 1013-1019. 
22. uuml, and ller, M. Microdialysis in clinical drug delivery studies, Advanced drug delivery 
reviews 45, 255-269. 
23. Cox, P. J., Ryan, D. A., Hollis, F. J., Harris, A.-M., Miller, A. K., Vousden, M., and 
Cowley, H. (2000) Absorption, Disposition, and Metabolism of Rosiglitazone, a Potent 
Thiazolidinedione Insulin Sensitizer, in Humans, Drug Metabolism and Disposition 28, 
772-780. 
24. Riccardi, K., Cawley, S., Yates, P. D., Chang, C., Funk, C., Niosi, M., Lin, J., and Di, L. 
(2015) Plasma Protein Binding of Challenging Compounds, Journal of Pharmaceutical 
Sciences 104, 2627-2636. 
25. Zhang, F., Xue, J., Shao, J., and Jia, L. (2012) Compilation of 222 drugs’ plasma protein 
binding data and guidance for study designs, Drug Discovery Today 17, 475-485. 
26. Fortuna, A., Alves, G., Soares-da-Silva, P., and Falcão, A. (2013) Pharmacokinetics, brain 
distribution and plasma protein binding of carbamazepine and nine derivatives: New set of 
data for predictive in silico ADME models, Epilepsy research 107, 37-50. 
181 
 
27. Plock, N. Microdialysis—theoretical background and recent implementation in applied 
life-sciences, European journal of pharmaceutical sciences 25, 1-24. 
28. Sun, L. An in vivo microdialysis coupled with liquid chromatography/tandem mass 
spectrometry study of cortisol metabolism in monkey adipose tissue, Analytical 
biochemistry 381, 214-223. 
29. Wang, C. Microdialysis combined with liquid chromatography–tandem mass spectrometry 
for the determination of levo-tetrahydropalmatine in the rat striatum, Journal of 
pharmaceutical and biomedical analysis 64-65, 1-7. 
 
 
 
 
 
